

Guidelines of care for the management of atopic dermatitis in pediatric patients



Dawn M. R. Davis, MD, (Co-Chair),^a Ali Alikhan, MD,^b Lionel Bercovitch, MD,^c David E. Cohen, MD, MPH,^d Jennifer M. Darr, LCSW,^e Aaron M. Drucker, MD, ScM,^{f,g} Lawrence F. Eichenfield, MD,^h Lindsay Frazer-Green, PhD,ⁱ Amy S. Paller, MD,^j Kathryn Schwarzenberger, MD,^k Jonathan I. Silverberg, MD, PhD, MPH,^l Anne Marie Singh, MD,^m Peggy A. Wu, MD, MPH,ⁿ and Robert Sidbury, MD, MPH, (Co-Chair)[†]

Background: Pediatric atopic dermatitis (AD) is a common, chronic inflammatory skin disorder that significantly impacts the quality of life of affected children and their families. Multiple therapies were approved to treat AD in children and adolescents since publication of the AAD's 2014 AD guidelines.

Objective: To provide evidence-based recommendations on the use of topical therapies, phototherapy, and systemic therapies for AD in children and adolescents.

Methods: A multidisciplinary workgroup conducted a systematic review and applied the GRADE approach for assessing the certainty of evidence and formulating and grading recommendations.

Results: The workgroup developed 27 evidence-based recommendations on the medical management of pediatric AD.

Limitations: This analysis is based on the best available evidence at the time it was conducted. Most randomized controlled trials of therapies for AD are of short duration limiting long-term efficacy and safety conclusions.

From the Departments of Dermatology and Pediatrics, Mayo Clinic, Rochester, Minnesota^a; Department of Dermatology, Sutter Medical Foundation, Sacramento, California^b; Department of Dermatology, Warren Alpert Medical School of Brown University, Providence, Rhode Island^c; The Ronald O. Perleman Department of Dermatology, New York University Grossman School of Medicine, New York, New York^d; Department of Pediatrics, National Jewish Health, Denver, Colorado^e; Division of Dermatology, Department of Medicine, University of Toronto, Toronto, Ontario, Canada^f; Research and Innovation Institute and Department of Medicine, Women's College Hospital, Toronto, Ontario, Canada^g; Departments of Dermatology and Pediatrics, University of California San Diego and Rady Children's Hospital San Diego, San Diego, California^h; American Academy of Dermatology, Rosemont, Illinoisⁱ; Departments of Dermatology and Pediatrics, Northwestern University Feinberg School of Medicine, Chicago, Illinois^j; Department of Dermatology, Oregon Health and Science University, Portland, Oregon^k; Department of Dermatology, The George Washington University School of Medicine and Health Sciences, Washington, District of Columbia^l; Department of Pediatrics, University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin^m; and Department of Dermatology, University of California, Davis, Sacramento, California.ⁿ

[†]Died July 11, 2025.

Funding sources: This study was funded in total by internal funds from the American Academy of Dermatology.

Patient consent: Not applicable.

IRB approval status: Not applicable.

Statement on prior presentation: Contents have not been previously presented.

Editorial note: Robert Sidbury, MD, MPH, passed away unexpectedly on July 11, 2025, after this manuscript was finalized for submission to the journal. The JAAD editor has confirmed that Dr Sidbury's contributions meet JAAD and ICMJE authorship criteria and that, to the best of the journal's knowledge, his disclosed conflicts are accurately represented.

Disclaimer: Adherence to these guidelines will not ensure successful treatment in every situation. Furthermore, these guidelines should not be interpreted as setting a standard of care or be deemed inclusive of all proper methods of care, nor exclusive of other methods of care reasonably directed to obtaining the same results. The ultimate judgment regarding the appropriateness of any specific therapy must be made by the physician and the patient in light of all the circumstances presented by the individual patient, and the known variability and biologic behavior of the disease. This guideline reflects the best available data at the time the guideline was prepared. The results of future studies may require revisions to the recommendations in this guideline to reflect new data.

Accepted for publication February 27, 2026.

Correspondence to: Lindsay Frazer-Green, PhD, American Academy of Dermatology, 9500 Bryn Mawr Ave, Suite 500, Rosemont, IL 60018. E-mail: guidelines@aad.org.

Published online April 7, 2026.

0190-9622/\$36.00

© 2026 by the American Academy of Dermatology, Inc.

<https://doi.org/10.1016/j.jaad.2026.02.113>

Conclusions: We make strong recommendations for the use of moisturizers, topical calcineurin inhibitors, topical corticosteroids, crisaborole ointment, roflumilast cream, ruxolitinib cream, tapinarof cream, dupilumab, tralokinumab, lebrikizumab, nemolizumab with concomitant topical therapy, upadacitinib, abrocitinib, and baricitinib in the treatment of pediatric AD. We make conditional recommendations in favor of bathing, bleach baths, wet dressings, phototherapy, methotrexate, mycophenolate mofetil, azathioprine, and cyclosporine. We conditionally recommend against the use of topical antimicrobials, PUVA phototherapy, and strongly recommend against systemic corticosteroids. (J Am Acad Dermatol 2026;95:121.e1-e26.)

Key words: antihistamines; antimicrobials; atopic dermatitis; azathioprine; bathing; biologic; calcineurin inhibitors; corticosteroids; cyclosporine; dupilumab; emollients; JAK inhibitor; methotrexate; phototherapy; topicals; wet wraps.

SCOPE AND OBJECTIVES

The American Academy of Dermatology (AAD) recently published guidelines for the care of AD in adults, addressing: (1) phototherapy and systemic therapies and (2) topical therapies.^{1,2} While pediatric and adult AD share similarities, these guidelines recognize the unique safety, dosing, and patient-caregiver-provider interactions of individuals under the age of 18. The scope of the present guidelines focuses solely on pediatric AD (<18 years of age).

Specifically, these guidelines provide evidence-based recommendations for topical therapies (prescription and non-prescription), phototherapy, and systemic therapies available in the United States. Children under 18 years of age with AD of any severity in any healthcare setting or context are the target population of these guidelines. Recommendations herein serve to update previously published guidelines.³⁻⁶

Topical therapies considered include non-prescription topical agents (eg moisturizers, bathing practices, and wet wraps) and pharmacologic topical modalities, including topical corticosteroids (TCS), topical calcineurin inhibitors (TCIs), Janus kinase inhibitors (JAKis), phosphodiesterase-4 (PDE-4) inhibitors, aryl hydrocarbon receptor agonists, antimicrobials and antihistamines. The use of ultraviolet (UVB), UVA1, and psoralen plus UVA (PUVA) phototherapy is assessed. Systemic therapies evaluated include immunosuppressants, corticosteroids, antineoplastic agents, JAKis, interferon gamma, immunoglobulin, and monoclonal antibodies (biologics).

METHODS

A multidisciplinary workgroup developed these guidelines using a systematic evidence review process, which included (i) identifying and prioritizing clinical

CAPSULE SUMMARY

- The guidelines provide child and adolescent specific recommendations for the management of atopic dermatitis with topical therapies, phototherapy, and systemic agents.
- Analysis of the evidence resulted in 27 evidence-based recommendations.

questions and outcomes (Table I), (ii) systematic retrieval and assessment of evidence, and (iii) assessment of the certainty of the evidence and formulation of recommendations using GRADE (Grading of Recommendations, Assessment, Development, and Evaluation) (Table II).

Existing, current, high-quality, relevant systematic reviews were identified via a systematic search, including a systematic review of bleach baths,¹⁰ 2 systematic reviews and network meta-analyses on topical treatments,^{11,12} and a living systematic review and network meta-analysis of systemic immunomodulatory treatments for AD.¹³ If relevant systematic reviews were not available, they were conducted de novo by the workgroup and AAD staff.

For detailed methodology, see Supplementary Appendix 1, available via Mendeley at <https://data.mendeley.com/datasets/fc2965fjb2/1>.

Definition

AD, also known as atopic eczema, is a chronic, pruritic inflammatory skin disease that occurs with highest prevalence in children. It follows a relapsing course. AD is often associated with a personal or family history of atopy.

MEDICAL MANAGEMENT

Reducing symptoms, specifically dermatitis and pruritus, and minimizing therapeutic risks, while enhancing quality of life (QoL) for patients and their caregivers, are key goals of pediatric AD management. To realize these goals, a variety of nonpharmacologic and pharmacologic therapies are available and evaluated in these guidelines.

The age ranges included in the clinical practice recommendations for the management of pediatric AD reflect FDA approvals and the ages of patients

Abbreviations used:

AAD:	American Academy of Dermatology
AD:	atopic dermatitis
AE:	adverse event
CDLQI:	Children's Dermatology Life Quality Index
CI:	confidence interval
EASI:	Eczema Area and Severity Index
FDA:	Food and Drug Administration
HR:	hazard ratio
IGA:	Investigator Global Assessment
JAKi:	janus kinase inhibitor
MMF:	mycophenolate mofetil
NB-UVB:	narrowband ultraviolet B
OR:	odds ratio
POEM:	Patient Oriented Eczema Measure
PUVA:	psoralen plus ultraviolet A
QoL:	quality of life
RCT:	randomized controlled trial
RR:	risk ratio
SAE:	serious adverse event
SCORAD:	Scoring of Atopic Dermatitis
TCI:	topical calcineurin inhibitor
TCS:	topical corticosteroids
UV:	ultraviolet

studied in clinical trials for the recommended therapies. These parameters provide a regulatory and evidence-based framework for treatment guidance. However, due to the inherent limitations of pediatric clinical research—including ethical considerations, smaller patient populations, and challenges in trial design—many effective therapies were not formally studied or approved in younger age groups. Consequently, in real-world pediatric dermatology practice, clinicians frequently use medications off-label, guided by the totality of evidence, clinical experience, and individual patient needs. This approach is essential to ensure timely and effective care for children across all age groups, even when formal approvals are lacking (Fig 1 and Table III).

TOPICAL THERAPIES

Optimal use of topical therapies is a cornerstone of AD management as these therapies are generally effective, and lower risk than systemic therapies. However, efficacy is dependent on consistency and appropriate usage/dosing (Table IV).

Non-prescription therapies

Moisturizers. The workgroup strongly recommends the use of moisturizers in AD but cannot recommend the use of a particular moisturizer, vehicle, or active ingredient based on the available evidence. (Supplementary Table I, available via Mendeley at <https://data.mendeley.com/datasets/fc2965fjb2/1>).

Analysis of 9 RCTs (1260 pediatric patients with AD) found moisturizers reduce AD disease severity as

assessed by Eczema Area Severity Index (EASI), Scoring of Atopic Dermatitis (SCORAD), and Total Symptom Score.^{15-17,20-22,25,30,33} Three RCTs (216 patients) found patients receiving moisturizer were more likely to achieve Investigator Global Assessment (IGA) 0 (clear) or IGA 1 (almost clear) over a follow-up period ranging from 3 to 6 weeks.^{16,19,30} Serious adverse events (SAEs) were rare, and moisturizers resulted in little to no difference in the number of participants experiencing an AE or discontinuing treatment due to AEs.^{14,16,17,19,20,22,25,28,30,33,37}

The use of moisturizers with TCS twice daily for 3 weeks does not appear to offer greater clinical improvement (SCORAD or Mean Global Condition Score) or improvement in QoL than TCS twice daily alone (Supplementary Table II, available via Mendeley at <https://data.mendeley.com/datasets/fc2965fjb2/1>).^{27,29} Moisturizer alone may result in a decrease in the number of clear or almost clear patients (IGA 0 or 1),²³ and an increase in the number of participants experiencing a flare.^{26,31,35} However, in 3 four-week RCTs, after treatment and stabilization of mild-to-moderate AD with 4 weeks of TCS, moisturizer alone (compared to moisturizer + TCS) achieved a similar mean SCORAD reduction, and similar Patient Oriented Eczema Measure (POEM),³¹ itch,³² and QoL scores as TCS alone.²⁶ (Supplementary Table III, available via Mendeley at <https://data.mendeley.com/datasets/fc2965fjb2/1>).^{18,31,36} Overall, adverse events and discontinuation were rare across the moisturizer-only and TCS and moisturizer treatment groups.^{18,23,24,26,31,35}

Of all non-prescription interventions, moisturizers have the strongest evidence, while also safe, affordable, and accessible. Public perception and support of moisturizers improve patient and caregiver engagement and compliance. Although allergenicity is always a theoretical risk (particularly for patients with AD), there are numerous hypoallergenic products available. It may be prudent to caution caregivers to avoid moisturizers with many additives (particularly plant-based additives which may be sensitizers).¹³⁹

Bathing practices. While bathing can be laborious for patients and families, the available data suggest it is safe, inexpensive, and reduces social stigma. That said, there is limited evidence of the efficacy of bathing in patients with AD compared to not bathing, or bathing with or without soap (Supplementary Tables IV and V, available via Mendeley at <https://data.mendeley.com/datasets/fc2965fjb2/1>). In 1 study of 58 pediatric patients with AD, washing with soap resulted in little difference in EASI or POEM scores.⁴⁰ Another small study found no difference in daily bathing versus twice weekly bathing in children with AD.⁴¹ Thus, we conditionally

Table I. Clinical questions and scope

Clinical questions		
1. What are the efficacy and safety of topical therapies for the management of AD in children and adolescents?		
2. What are the efficacy and safety of phototherapy or photochemotherapy for the treatment of AD in children and adolescents?		
3. What are the efficacy and safety of systemic therapies for the treatment of AD in children and adolescents?		
Outcomes of interest for therapy questions		
Efficacy outcomes	Change in clinical signs/symptoms of disease as assessed by a clinician Prevention of flares	
Patient-reported outcomes	Change in patient-reported signs/symptoms Change in quality of life Change in itch severity	
Safety outcomes	Serious adverse events Withdrawal due to adverse events Infection	
Scope for therapy questions		
Characteristic	Inclusion criteria	Exclusion criteria
Population	Children and adolescents (<18 y of age) with a clinical diagnosis of AD (including “eczema” or “atopic eczema”)	Immunocompromised patients, contact dermatitis, seborrheic dermatitis, varicose eczema, discoid eczema; infected atopic dermatitis
Intervention	Topical, systemic, or phototherapy/photochemotherapy interventions available and approved for use (for any indication) in the US	Treatments not available or approved for use (for any indication) in the US
Study Design	Published RCTs in which study participants are investigated (inter-individual, parallel-arm trials)	Unpublished research, observational studies, case series, case reports, modeling studies, narrative reviews

recommend bathing for treatment and maintenance for pediatric patients with AD, but we cannot recommend a standard frequency or duration of bathing based on the paucity of data. In patients with AD, it may be advisable to use a hypoallergenic cleanser with fewer ingredients designed for sensitive skin.

A 16-week RCT of 461 patients found bath additives result in little to no difference in POEM score or QoL and may increase AEs slightly (Supplementary Table VI, available via Mendeley at <https://data.mendeley.com/datasets/fc2965fjb2/1>).⁴² Emollient use after bathing is a standard practice among providers caring for patients with AD. An RCT of 84 patients found twice daily soak and seal baths (15–20 minutes) resulted in a larger SCORAD reduction than twice weekly soak and seal baths (10 minutes or less) (Supplementary Table VII, available via Mendeley at <https://data.mendeley.com/datasets/fc2965fjb2/1>).³⁹ Quality of life, as assessed by patients and caregivers, did not differ meaningfully between groups.

Bleach baths. For pediatric patients with AD, we conditionally recommend dilute bleach (sodium hypochlorite) baths under the guidance of a healthcare

professional skilled in AD management. The data are limited with serious imprecision given the small sample sizes of the included studies. (Supplementary Table VIII, available via Mendeley at <https://data.mendeley.com/datasets/fc2965fjb2/1>).

Meta-analysis of 8 RCTs including unpublished data found bleach baths may improve clinician rating of AD severity (EASI) possibly by reducing *Staphylococcus* colonization and/or increasing microbial flora diversity, but seem to have minimal impact on POEM score, itch response, and QoL.¹⁰ Bleach baths were found to be safe with few, if any, AEs. Diluting the bleach is important as bleach alone can be caustic, causing burns, itch, and dryness. In sum, bleach baths are low-risk, readily accessible, and inexpensive. Two important points to consider: (1) bleach bathing appears to reduce *Staphylococcus* colonization but its effect on infection is less clear, and (2) a plain water bath may not be less advantageous than a bleach bath.^{140–142}

Wet wrap therapy. The workgroup conditionally recommends use of wet dressings under the guidance of a healthcare professional skilled in the

Table II. Strength of recommendation and certainty of evidence

Strength of recommendation	Wording	Implication ^{7,9}
<i>Strong recommendation for the use of an intervention</i>	"We recommend..."	Benefits clearly outweigh risks and burdens; recommendation applies to most patients in most circumstances.
<i>Strong recommendation against the use of an intervention</i>	"We recommend against..."	Risk and burden clearly outweigh benefits; the recommendation applies to most patients in most circumstances.
<i>Good Practice Statement</i>	"We recommend..."	Guidance was viewed by the Workgroup as imperative to clinical practice and developed when the supporting evidence was considerable but indirect, and the certainty surrounding an intervention's impact was high with the benefits clearly outweighing the harms (or vice versa). Good Practice Statements are strong recommendations as the certainty surrounding the impact of the recommended intervention is high. Implementation of these strong recommendations is considered to clearly result in beneficial outcomes. ⁹
<i>Conditional recommendation for the use of an intervention</i>	"We conditionally recommend..."	Benefits are closely balanced with risks and burdens; recommendation applies to most patients, but the most appropriate action may differ depending on the patient or other stakeholder values.
<i>Conditional recommendation against the use of an intervention</i>	"We conditionally recommend against..."	Risks and burden closely balanced with benefits; recommendation applies to most patients, but the most appropriate action may differ depending on the patient or other stakeholder values
Certainty of evidence	Wording	Implication ^{7,8}
High	"high certainty evidence"	Very confident that the true effect lies close to that of the estimate of the effect.
Moderate	"moderate certainty evidence"	Moderately confident in the effect estimate; the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.
Low	"low certainty evidence"	Confidence in the effect estimate is limited; the true effect may be substantially different from the estimate of the effect
Very Low	"very low certainty evidence"	The estimate of effect is very uncertain; the true effect may be substantially different from the estimate of effect

management of AD (Supplementary Table IX, available via Mendeley at <https://data.mendeley.com/datasets/fc2965fjb2/1>). The addition of wet dressings with TCS is typically encouraged during AD flares, rather than as maintenance therapy.

Hindley et al, the only included study, is specific to the inpatient setting.⁴³ The experimental group in this study received 1 week of wet wraps applied daily for 24 hours over 1% hydrocortisone ointment (and if necessary, more potent topical steroids), followed by

wet wraps for 12 or 24 hours a day depending on progress; the control group received conventional AD treatment (regular use of emollients applied at least 3 times a day; 1% hydrocortisone ointment applied twice daily and use of more potent topical steroids if necessary). Wet wrap therapy resulted in little to no difference in the mean SCORAD score. However, wet wrap therapy was used for maintenance rather than flares (where it would probably be more effective), and the control group still used treatments as needed.




Fig 1. Treatment algorithm for children and adolescents with atopic dermatitis. FDA, Food and Drug Administration; QoL, quality of life. *Disclaimer:* Age ranges reflect FDA indication and/or ages of patients studied in clinical trials. Many therapies with demonstrated efficacy and safety in older children or adults are commonly used off-label in pediatric dermatology practice. Such use is guided by clinical judgment, available literature, and the need to provide effective, individualized care despite the absence of formal regulatory approval for certain age groups.

Table III. Recommendations for the medical management of atopic dermatitis in children and adolescents

Recommendation	Strength	Certainty of evidence	Evidence
Nonprescription topical interventions			
For pediatric patients up to age 18 with AD, we recommend the use of moisturizers. <i>Remark:</i> The use of a particular moisturizer, vehicle, or active ingredient cannot be recommended based on the available evidence.	Strong	Moderate	14-38
For pediatric patients up to age 18 with AD, we conditionally recommend bathing for treatment and maintenance. <i>Remark:</i> A standard for the frequency or duration of bathing appropriate for individuals with AD cannot be established based on the current available evidence.	Conditional	Very low	39-42
For pediatric patients up to age 18 with AD, we conditionally recommend dilute bleach (sodium hypochlorite) baths under the guidance of a healthcare professional skilled in the management of AD.	Conditional	Very low	10
For pediatric patients up to age 18 with AD, we conditionally recommend the use of wet dressings under the guidance of a health care professional skilled in the management of AD. <i>Remark:</i> The addition of wet dressings with topical corticosteroids is typically encouraged during AD flares rather than as maintenance therapy. Evidence is not available for the optimal method of wet dressing therapy.	Conditional	Low	43
Topical antimicrobials			
We conditionally recommend <i>against</i> the use of topical antimicrobials for AD without signs of infection in pediatric patients up to the age of 18.	Conditional	Very low	11,44
Topical calcineurin inhibitors			
For pediatric patients up to the age of 18, we recommend the use of topical calcineurin inhibitors (tacrolimus, pimecrolimus).	Strong	Moderate	45-61
For pediatric patients up to the age of 18, we recommend proactive use of intermittent TCIs as maintenance therapy.	Strong	Moderate	55,61-68
Topical corticosteroids			
For pediatric patients up to age 18 with AD, we recommend topical corticosteroids.	Strong	Moderate	32,58,59,69-77
For pediatric patients up to age 18 with AD, we recommend intermittent use of low to medium potency topical corticosteroids as maintenance therapy (up to 3 times per wk).	Strong	Moderate	26,78,79
Topical phosphodiesterase-4 inhibitors			
For pediatric patients 3 mo and older with mild-to-moderate AD, we recommend the use of crisaborole.	Strong	Moderate	59,80-87
For pediatric patients aged 2 y and older with mild-to-moderate AD, we recommend the use of roflumilast cream.	Strong	High	88-90
Topical JAK inhibitors			
For pediatric patients aged 2 y and older with mild-to-moderate AD, we recommend ruxolitinib cream.	Strong	High	91,92
Topical aryl hydrocarbon receptor agonists			
For pediatric patients aged 2 y and older with AD, we recommend tapinarof cream.	Strong	High	93-95
Phototherapy			
For pediatric patients up to age 18 with AD, we conditionally recommend phototherapy	Conditional	Low	96,97

Continued

Table III. Cont'd

Recommendation	Strength	Certainty of evidence	Evidence
For pediatric patients up to age 18 with AD, we conditionally recommend <i>against</i> PUVA phototherapy <i>Remark:</i> PUVA phototherapy should be avoided if other modalities are available given the recognized long-term safety effects, specifically the increased risk of UV-induced SCCs and photoaging.	Conditional	Very low	97
Monoclonal antibodies (biologics)			
For pediatric patients 6 mo and older with moderate-to-severe AD, we recommend dupilumab <i>Remark:</i> There is less efficacy and safety data on children aged 6 mo to <2 y.	Strong	Moderate	98-101
For pediatric patients 12 y and older with moderate-to-severe AD, we recommend tralokinumab	Strong	Moderate	102
For pediatric patients 12 y and older with moderate-to-severe AD, we recommend lebrikizumab	Strong	Moderate	103-105
For pediatric patients 12 y and older with moderate-to-severe AD, we recommend nemolizumab with concomitant topical therapy	Strong	Moderate	106,107
JAK inhibitors			
For pediatric patients 12 y and older with moderate-to-severe AD, we recommend upadacitinib <i>Remark:</i> Upadacitinib is approved by the FDA in patients aged 12 and older with AD who have failed other systemic therapies (pills or injections, including biologics) or when use of those therapies is inadvisable.	Strong	Moderate	108-112
For pediatric patients 12 y and older with moderate-to-severe AD, we recommend abrocitinib <i>Remark:</i> Abrocitinib is approved by the FDA in patients aged 12 and older with AD who have failed other systemic therapies (pills or injections, including biologics) or when use of those therapies is inadvisable.	Strong	Moderate	113-117
For pediatric patients 12 y and older with moderate-to-severe AD, we recommend baricitinib <i>Remark:</i> Baricitinib is not approved by the FDA for use in AD but is approved by the European Medicines Agency for ages 2 y and older. The recommended age range reflects FDA indications for other drugs in the same class.	Strong	Moderate	118
Immunosuppressants			
For pediatric patients 2 y and older with moderate-to-severe AD, we conditionally recommend methotrexate with proper monitoring <i>Remarks:</i> Comorbidities or drug interactions that may exacerbate toxicity make this intervention inappropriate for select patients. In the US, the FDA has not approved methotrexate for use in AD.	Conditional	Low	119,120
For pediatric patients up to 18 y with refractory moderate-to-severe AD, we conditionally recommend mycophenolate mofetil* with proper monitoring <i>Remarks:</i> Mycophenolate mofetil is not approved by the FDA for use in AD. Comorbidities or drug interactions that may exacerbate toxicity make this intervention inappropriate for select patients.	Conditional	Very low	121,122
For pediatric patients up to 18 y with refractory moderate-to-severe AD, we conditionally recommend limited-term use of azathioprine with proper monitoring and prescreening of thiopurine methyltransferase activity <i>Remark:</i> Comorbidities or drug interactions that may exacerbate toxicity make this intervention inappropriate for select patients.	Conditional	Very low	123,124

Continued

Table III. Cont'd

Recommendation	Strength	Certainty of evidence	Evidence
For pediatric patients up to 18 y with refractory moderate-to-severe AD, we conditionally recommend limited-term use of cyclosporine with proper monitoring <i>Remarks:</i> The FDA has not approved cyclosporine for use in AD. The FDA has approved limited-term use (up to 1 y) in psoriasis. Cyclosporin is authorized in several European countries for the systemic treatment of severe AD, generally in patients aged 16 y and older, with specific indications defined at the national level. Comorbidities or drug interactions that may exacerbate toxicity make this intervention inappropriate for select patients.	Conditional	Low	125-129
For pediatric patients up to 18 y with AD, we recommend <u>against</u> systemic corticosteroids <i>Remarks:</i> Their use should be reserved exclusively for acute, severe exacerbations and as a short-term bridge therapy for other systemic, corticosteroid-sparing therapy. Systemic corticosteroids should not be used as maintenance therapy.	Good Practice Statement		

The underline is intended to highlight recommendations against an intervention as opposed to the majority of recommendations for interventions.

AD, Atopic dermatitis; FDA, Food and Drug Administration; PUVA, psoralen plus ultraviolet A; SCC, squamous cell carcinoma.

*Mycophenolic acid can be used interchangeably depending on availability. Note that dosing differs for mycophenolic acid and mycophenolate mofetil.

Other limitations include the narrow age range of patients, and the fact that children in this age group are often fully clothed, such that clothing provides a partial dressing *de facto*.

Wet wrap therapy can be labor- and time-intensive for caregivers, and prolonged or continuous use may limit daily activities for patients. Therapy considerations include steroid potency (wet dressings can potentiate TCS), temperature control, and overall safety. It is important to consider infant-specific safety issues (dressing in layered pajamas may result in strangulation, hypothermia, etc.), skin maceration, and discomfort. Moreover, evidence is not available for the optimal method of wet dressing therapy.

Topical calcineurin inhibitors

Topical calcineurin inhibitors are a mainstay in pediatric AD treatment due to their favorable safety profile and lack of atrophy as a possible side effect. Tacrolimus ointment topically comes in 0.03% and 0.1% strengths, while pimecrolimus cream comes as a 1% formulation. Topical calcineurin inhibitors can be effective for both AD flares and intermittently as maintenance therapy (Supplementary Tables X-XV, available via Mendeley at <https://data.mendeley.com/datasets/fc2965fjb2/1>).

Tacrolimus. Two RCTs (3-12 weeks) with over 300 children with moderate-to-severe AD demonstrated tacrolimus 0.1% ointment increases the number of participants cleared or with excellent

improvement - 256 more patients per 1000 (95% CI from 27 fewer to 1000 more) compared to placebo-while also resulting in a clinically meaningful reduction in itch and low discontinuation rate (Supplementary Table X, available via Mendeley at <https://data.mendeley.com/datasets/fc2965fjb2/1>).^{45,48} Data on tacrolimus 0.03% ointment are similar in terms of efficacy and itch response, with low incidence of AEs. Events of interest included herpes simplex and stinging/burning.^{45,46,48,49} Furthermore, tacrolimus use is unlikely to increase the risk of cancer in pediatric or adult patients with AD, based on 64 non-randomized studies.⁴⁷ Of note, there do not appear to be additional risks, other than local effects, in children applying tacrolimus 0.1% ointment compared to those applying 0.03% ointment.^{48,130-137}

TCIs may also be used for AD maintenance therapy. In a study of tacrolimus 0.03% ointment twice weekly proactively for 12 months versus vehicle in children aged 2 to 15 years with mild-to-severe AD, use of tacrolimus reduced the number of individuals experiencing a flare (RR 0.70 [95% CI: 0.57-0.87]); serious adverse events were rare and AEs similar between groups.⁶² Pruritus and impetigo were reported more often with tacrolimus, but herpes simplex rates were comparable.

Pimecrolimus. Pooling data from 8 RCTs (2637 patients) comparing pimecrolimus 1% cream twice daily for 2 to 14 weeks to vehicle in mild-to-moderate patients with AD aged 3 months to 17 years

Table IV. Medication dosing table for use in children and adolescents

Medication (FDA age of indication)	Dose	Notes
Tacrolimus ointment 0.03% (≥ 2 y)	bid to affected skin	Reassess at 6 wk; Do not use with occlusive dressing
Tacrolimus ointment 0.1% (≥ 16 y)	bid to affected skin	Studies have demonstrated safety in children 2 y and younger, despite lack of FDA approval in this age group ^{48,130-137} ; Do not use occlusive dressing
Pimecrolimus cream 1% (≥ 2 y)	bid to affected skin	Reassess at 6 wk; Do not use with occlusive dressing
Crisaborole ointment 2% (≥ 3 mo)	bid to affected skin	Once clinical effect is achieved consider reducing application to qd
Roflumilast cream 0.05% (2-5 y) and 0.15% (≥ 6 y)	qd to affected skin	
Ruxolitinib cream 1.5% (≥ 2 y)	bid to affected skin; >12 y maximum of 60 g/2k, 100 g/2 wk; 2-12y maximum 60 g/2 wk	Treatment area should not exceed 20% BSA; reassess at 24 wk
Tapinarof cream 1% (≥ 2 y)	qd to affected skin*	FDA-approved for plaque psoriasis in adults
Topical corticosteroids	qd to bid for flares; maintenance therapy may involve up to 3 times per wk application; Use fingertip unit (FTU) guidance; avoid overuse to prevent skin thinning	Infants and young children have higher absorption; prefer low-potency steroids and limit duration; Use low-potency steroids for the face and intertriginous areas; medium potency (eg, triamcinolone 0.1%) for the body; high-potency only for severe flares and short durations
Dupilumab (≥ 6 mo)	6 mo-5 y, 5-14 kg 200 mg SC q4wk 6 mo-5 y, 15-29 kg 300 mg SC q4wk 6-17 y, 15-29 kg 600 mg SC $\times 1$ on day 1, then 300 mg SC q4wk 6-17 y, 30-59 kg 400 mg SC $\times 1$ on day 1, then 200 mg SC q2wk 6-17 y, >60 kg 600 mg SC $\times 1$ on day 1, then 300 mg SC q2wk	
Talokinumab (≥ 12 y)	300 mg SC $\times 1$ on day 1, then 150 mg SC q2wk	
Lebrikizumab (≥ 12 y)	500 mg SC $\times 1$ on wk 0, 2, then 250 mg SC q2wk	Dose specified for individuals >40 kg. If adequate clinical response at 16 wk consider once monthly dosing
Nemolizumab (≥ 12 y)	60 mg SC $\times 1$ on day 1, then 30 mg SC q4wk	Concomitant use of optimized prescription topical therapy is recommended; After 16 wk of treatment, for patients who achieve clear or almost clear skin, a dosage of 30 mg q8wk is recommended
Upadacitinib (≥ 12 y)	15 or 30 mg PO qd	Dose specified for individuals >40 kg; may increase to 30 mg PO qd if inadequate response
Abrocitinib (≥ 12 y)	100 or 200 mg PO qd	Dose specified for individuals >25 kg; Start with 100 mg PO qd, increase to 200 mg PO qd if needed; use lowest effective dose
Baricitinib (Off-label)	2 mg or 4 mg PO qd*	Approved for use for AD in adults and children ≥ 2 y of age in Europe

Continued

Table IV. Cont'd

Medication (FDA age of indication)	Dose	Notes
Methotrexate (Off-label)	10-15 mg PO or SC weekly [†]	Once control is achieved, lower dose to lowest possible effective dose. Despite broad usage, there is a lack of consensus on dosing for AD. Folic acid supplementation recommended to reduce side effects.
Mycophenolate mofetil (Off-label)	Up to 3000 mg PO daily, divided BID	Mycophenolate mofetil oral products are not interchangeable w/mycophenolic acid delayed release products; do not substitute on a mg-to-mg basis
Azathioprine (Off-label)	2-3.5 mg/kg PO daily in patients with normal levels of thiopurine methyltransferase*	Thiopurine methyltransferase genotype or enzyme activity should be checked before treatment initiation and the dose lowered, or the medication not started, depending on the results.
Cyclosporine (Off-label)	2.5-5 mg/kg PO daily*	Start at the higher end of dosing range and decrease once control is achieved. Use is generally limited to 1 yr. Prescribers should be aware of whether the modified or non-modified form of cyclosporine is being dispensed as this can alter bioavailability, efficacy, and safety.

bid, Twice daily; *FDA*, Food and Drug Administration; *mo*, month; *PO*, by mouth; *qd*, once daily; *SC*, subcutaneous; *wk*, week.

*Based on dosing in clinical trials of the management of AD in children and/or adolescents.

[†]Based on dosing recommendations in 18 dermatological guidelines with explicit consideration of the dosing regimen of MTX for AD in children.¹³⁸

demonstrates significantly more patients using pimecrolimus achieved IGA 0/1 (RR 1.87 [95% CI: 1.33-2.61]).^{50,51,53-55,58,60,61} Furthermore, in 4 RCTs, significantly more patients achieved no to mild itch following pimecrolimus treatment.^{51,53-55} From a safety standpoint, pimecrolimus resulted in little to no difference in SAEs, withdrawals due to AEs were rare and comparable across treatment groups, and application site burning occurred at a similar rate across treatment groups.^{51,52,54,56,58}

Pimecrolimus 1% cream is effective and safe for long-term (24-52 weeks) use as well. Four RCTs (1689 patients) demonstrated long-term use of pimecrolimus reduces AD exacerbations (RR 1.65 [95% CI 1.47-1.85]).^{61,65,67} Long-term pimecrolimus use may also increase the number of patients achieving IGA 0/1 and no or mild itch while reducing SAEs and withdrawals due to AEs.^{61,63,65-68}

TCI use in children under 2 years of age. While Food and Drug Administration (FDA) approval of TCIs (both tacrolimus and pimecrolimus) is for ages 2 years and over, their use in children under 2 years is supported by several nonrandomized and clinical studies (Supplementary Table XV, available via Mendeley at <https://data.mendeley.com/datasets/fc2965fjb2/1>); other countries have

approved use in children as young as 3 months. Burning and stinging are documented side effects, and application site reactions may limit use—this may occur more with tacrolimus ointment than pimecrolimus cream. The boxed warning on TCIs may also pose a potential concern for caregivers; providers should discuss that while the medications carry a boxed warning of cancer, the warning is based on theoretical risks from high-dose systemic calcineurin inhibitors used in post-transplant patients, and there is no evidence of a causal relationship between TCIs and malignancy.^{47,143-145} In 2021, Health Canada removed the boxed warning of a potential association of TCIs and malignancy following a review of current data, including 2 large, long-term, post-authorization safety studies, which indicate no evidence of an increased rate of lymphoma with the use of TCIs.^{146,147}

Topical corticosteroids

Topical corticosteroids are a mainstay of AD treatment in children and adults, and the evidence supports a recommendation in favor of their use for the management of AD in children and adolescents

(Supplementary Tables XVI–XXI, available via Mendeley at <https://data.mendeley.com/datasets/fc2965fjb2/1>). They have the longest track record of any FDA-approved pediatric AD treatment and are safe and effective when used appropriately. While concerns about side effects, particularly atrophy, are valid, TCS are commonly considered first-line in most cases due to affordability and accessibility. Anatomical site is an important consideration when selecting a TCS potency (ie using lower potency agents on the face, neck, genitals, and body folds). While some dermatologists prefer high and very high potency steroids (at least initially) to control active disease, others use the lowest potency agent needed for the situation and increase potency if needed (Table V).

High potency and very high potency topical steroids. Higher rates of AEs are associated with higher potency TCS — while atrophy is the most discussed, hypothalamic-pituitary-adrenal axis suppression is also a consideration. Nevertheless, high potency TCS can be extremely effective in rapidly controlling flares and may be a good option for older children. In adolescents (aged 12–17 years) with moderate-to-severe AD, compared to placebo, clobetasol propionate 0.05% foam twice daily for 2 weeks resulted in a large increase in the proportion of patients achieving an IGA of 0 or 1 (RR 5.87 [95% CI: 1.96–17.61]), but increased treatment-emergent AEs slightly (RR 1.39 [95% CI: 0.30–6.52]).⁶⁹

Medium potency topical steroids and maintenance therapy. Medium potency TCS are an effective, safer alternative to high potency TCS. In children aged 1 to 12 months with infantile facial AD ($n = 36$), mometasone furoate 0.1% cream twice daily for 10 days was found to be safe with a side effect profile similar to vehicle, and resulted in a greater improvement in EASI scores, itch response and QoL.⁷⁰ Similar safety and efficacy were reported with fluticasone propionate 0.05% cream twice daily for 4 weeks in children and adolescents (aged 6 months to 18 years) with moderate-to-severe AD.³²

Medium potency TCS are also recommended for maintenance therapy (Table III). Maintenance therapy aims to reduce flares and relapses while minimizing AEs from overuse of TCS. In studies ranging from 16 to 20 weeks in patients ≥ 1 year of age, fluticasone propionate 0.05% cream daily twice per week reduced SCORAD (Mean difference 9.3 lower [95% CI: 0.49 lower to 18.15 lower]) and numerically reduced the number of patients experiencing disease exacerbations (360 fewer per 1000 [95% CI: 494 fewer to 84 more]), with a safety and discontinuation profile similar to the emollient comparator (Supplementary Table XIX, available via Mendeley at <https://data.mendeley.com/datasets/fc2965fjb2/1>).^{26,78,79}

Lower medium potency and low potency topical steroids. While high potency and medium potency TCS work quickly, they may increase AEs, particularly in younger pediatric patients. For these patients as well as those with mild AD, lower medium potency and low potency TCS can be an effective option.

In several studies, hydrocortisone butyrate 0.1% cream twice daily for 4 weeks in patients ranging from 3 months to 18 years was effective in reducing EASI and itch, with rare SAEs and discontinuation.^{59,71,73} Additionally, fluticasone 0.05% cream twice weekly for 16 weeks reduced AD exacerbations (RR 0.19 [95% CI: 0.11–0.35]).⁷² Even weaker steroids such as hydrocortisone 1%, fluocinolone 0.01%, and desonide 0.05% applied twice daily to affected skin can be effective in milder cases and younger patients. In patients with mild disease, low-potency steroids can significantly reduce SCORAD, itch, and flares with fewer AEs than higher-potency TCS.^{58,74–77}

Adverse effects and monitoring. Many caregivers and patients may be afraid to use TCS, and many providers may be fearful of potential cutaneous and systemic AEs. A systematic review and patient panel found patients with AD value non-corticosteroid therapies. When using TCS, they prefer to use the medications for the minimum amount of time possible and place a high value on rapidly relieving itch.¹⁴⁹ Using a Likert scale to document TCS concerns, patients with AD and caregivers ranked their distress level a 6.5/10 on average (with 10 as the highest level of distress/concern).¹⁵⁰

When used appropriately, TCS are safe and effective. It is important to keep in mind the patient's age, disease severity, body surface area, and steroid potency. Appropriate treatment may require using a moderate or high potency steroid for several weeks. In patients with frequently relapsing disease, lower and medium potency TCS can be used as maintenance therapy up to 3 times per week to help reduce disease flares and increase comfort.

Topical antimicrobials

Antimicrobials. Topical antimicrobials are often requested due to concern of infection or the impression they are a standard of care. Moreover, many non-dermatologists prescribe topical antimicrobials (or recommend non-prescription antimicrobial products) for use on AD skin. The workgroup conditionally recommends against the use of topical antimicrobials (antifungals and antibiotics) for AD without signs of infection in pediatric patients (Table III).

Our recommendation focuses on uninfected skin, which is different than infected skin (ie, with overt

Table V. Relative potencies of topical corticosteroids

Class	Drug	Dosage form(s)	Strength (%)
I. Very high potency	Augmented betamethasone	Ointment	0.05
	dipropionate clobetasol propionate	Cream, foam, ointment	0.05
	Diflorasone diacetate	Ointment	0.05
	Halobetasol propionate	Cream, ointment	0.05
II. High potency	Amcinonide	Cream, lotion, ointment	0.1
	Augmented betamethasone dipropionate	Cream	0.05
	Betamethasone dipropionate	Cream, foam, ointment, solution	0.05
	Desoximetasone	Cream, ointment	0.25
	Desoximetasone	Gel	0.05
	Diflorasone diacetate	Cream	0.05
	Fluocinonide	Cream, gel, ointment, solution	0.05
	Halcinonide	Cream, ointment	0.1
	Mometasone furoate	Ointment	0.1
	Triamcinolone acetonide	Cream, ointment	0.5
	Betamethasone valerate	Cream, foam, lotion, ointment	0.1
	Clocortolone pivalate	Cream	0.1
	Desoximetasone	Cream	0.05
	Fluocinolone acetonide	Cream, ointment	0.025
III-IV. Medium potency	Flurandrenolide	Cream, ointment	0.05
	Fluticasone propionate	Cream	0.05
	Fluticasone propionate	Ointment	0.005
	Mometasone furoate	Cream	0.1
	Triamcinolone acetonide	Cream, ointment	0.1
	Hydrocortisone butyrate	Cream, ointment, solution	0.1
	Hydrocortisone probutate	Cream	0.1
	Hydrocortisone valerate	Cream, ointment	0.2
	Prednicarbate	Cream	0.1
	Alclometasone dipropionate	Cream, ointment	0.05
V. Lower medium potency	Desonide	Cream, gel, foam, ointment	0.05
	Fluocinolone acetonide	Cream, solution, oil	0.01
	Dexamethasone	Cream	0.1
VI. Low potency	Hydrocortisone	Cream, lotion, ointment, solution	0.25, 0.5, 1, 2.5
	Hydrocortisone acetate	Cream, ointment	0.5-1

Reprinted with permission from: Paller and Mancini.¹⁴⁸ Copyright 2011 Elsevier. Includes representative examples and not all available agents.

impetiginization or cellulitis) that would clearly benefit from antimicrobial therapy. There are limited data on this topic, and there are concerns about antimicrobial stewardship and contact allergen sensitivity development risk, particularly on the impaired skin barrier in AD. Additionally, body surface area is an important consideration in deciding whether to treat with topical antimicrobials or systemic antibiotics.

While there is no direct pediatric-specific evidence to assess the efficacy and safety of topical antibiotics for uninfected AD, a systematic review suggests topical antibiotic use likely results in no meaningful difference from control in SCORAD, itch score, rate of flares, and QoL in individuals of any age with uninfected AD (Supplementary Table XXII, available via Mendeley

at <https://data.mendeley.com/datasets/fc2965fjb2/1>).¹¹ Specific to topical antifungals, in a study of 29 pediatric patients with AD, hydrocortisone 1% plus miconazole cream twice daily for 2 weeks did not outperform hydrocortisone 1% cream alone twice daily for 2 weeks in terms of investigator- or patient-assessed response (Supplementary Table XXIII, available via Mendeley at <https://data.mendeley.com/datasets/fc2965fjb2/1>).⁴⁴

Topical phosphodiesterase inhibitors

Crisaborole. Crisaborole, a phosphodiesterase-4 inhibitor, is a safe and effective non-steroidal treatment option for patients with AD 3 months and older (Supplementary Table XXIV, available via Mendeley at <https://data.mendeley.com/datasets/>

fc2965fjb2/1). In clinical trials, crisaborole reduced EASI scores (mean % change -26.62), POEM scores, and itch, and resulted in more patients achieving IGA 0 or 1 (RR 1.53 [95% CI: 1.25-1.87]).^{59,82-84} Daily, long-term (52 weeks) use decreased flares ($P = .0042$) and increased flare-free maintenance ($P = .0034$), without safety concerns beyond those seen in shorter-term trials.⁸⁰ Crisaborole resulted in little to no difference in discontinuation vs vehicle and no SAEs were reported across groups in clinical trials.^{82,83} However treatment-related AEs appear to be more common with crisaborole, particularly application site pain.^{82,83} Tolerance is a critical issue, particularly as application site burning and stinging are documented side effects and application site reactions may limit use.^{86,151,152}

Roflumilast. Roflumilast is another phosphodiesterase-4 inhibitor. The workgroup recommends the use of roflumilast cream for children aged 2 years and older with mild-to-moderate AD (Table III). In alignment with current FDA indications, the trials investigated the use of roflumilast 0.15% in children aged ≥ 6 years and roflumilast 0.05% in children aged 2-5 years. Four RCTs found significantly more patients achieved EASI 75 (RR 2.02 [95% CI: 1.72-2.37]), IGA 0 or 1, and clinically meaningful itch reduction using roflumilast daily for 28 days compared to vehicle (Supplementary Table XXV, available via Mendeley at <https://data.mendeley.com/datasets/fc2965fjb2/1>).⁸⁸⁻⁹⁰ Discontinuation was rare, with similar rates between groups, and the rates of treatment-emergent AEs of interest were not meaningfully higher in participants receiving roflumilast.⁸⁸⁻⁹⁰ Roflumilast does not have the same degree of application site pain and burning as crisaborole. In a 52-week open-label extension, proactive treatment of roflumilast (twice weekly application to normal-appearing flare-prone sites) maintained improvement in AD signs and symptoms; this use of the medication may keep skin clearer in a more consistent manner than the current practice of reactive treatment.¹⁵³

Topical JAK inhibitors

Ruxolitinib is approved for pediatric patients aged 2 years and older whose disease is not adequately controlled with other topical prescription therapies, or when those therapies are not advisable. Across 3 RCTs, ruxolitinib 1.5% cream twice daily for 8 weeks reduced EASI scores, resulted in a large increase in the proportion of patients achieving IGA 0 or 1, and increased the number of patients achieving a meaningful itch response compared with vehicle (Supplementary Table XXVI, available via Mendeley at <https://data.mendeley.com/datasets/fc2965fjb2/1>).

fc2965fjb2/1).^{91,92} Furthermore, in a large meta-analysis of topical anti-inflammatory treatments for AD in adults and children, ruxolitinib was similar in efficacy to potent topical steroids (ie betamethasone valerate 0.1%, betamethasone dipropionate 0.05%), and tacrolimus 0.1%.¹⁵⁴ Serious adverse events and withdrawal due to AEs are uncommon with rates similar to those of patients receiving vehicle. Furthermore, uncontrolled long-term data (52 weeks) indicate ruxolitinib maintains disease control while continuing to be safe with few treatment-related AEs.¹⁵⁵

Topical ruxolitinib carries a boxed warning based on adverse events reported with the oral JAK inhibitor tofacitinib (serious side effects — infections, blood clots, cancer, and heart disease). While topical ruxolitinib appears to be safe, other options should be considered first in patients with risk factors for serious infections, cancer, thrombosis, or cardiovascular events. Suggested use is limited to 20% body surface area due to the bioavailability and systemic absorption concerns.

Topical aryl hydrocarbon receptor agonist

Tapinarof is a first-in-class topical aryl hydrocarbon receptor agonist approved for patients aged 2 years and older with mild, moderate or severe AD. Pediatric-specific evidence aligned with our inclusion criteria was not available. However, the ADORING trials included patients aged 2 years and older with moderate-to-severe AD, and over 80% of the participants were children.⁹⁵ Additional data (particularly relating to AEs) were derived from a trial of 12 to 65 year olds (13% of the study population was between 12 and 17 years of age) (Supplementary Table XXVII, available via Mendeley at <https://data.mendeley.com/datasets/fc2965fjb2/1>).⁹⁴

In the ADORING trials, tapinarof increased the number of patients achieving EASI 75 (RR 2.60 [95% CI: 2.06-3.29]), a meaningful itch response (RR 1.77 [95% CI: 1.43-2.19]), and a meaningful vIGA-AD response (RR 2.89 [95% CI: 2.16-3.86]) compared to vehicle.⁹⁵ Although SAEs, were rare and rates of withdrawal due to AEs were similar between groups, tapinarof increased treatment-related AEs slightly.^{94,95} Follicular cutaneous AEs (eg folliculitis, acneiform lesion) can occur and should be discussed when prescribing.

PHOTOTHERAPY

While phototherapy is an effective and safe method to treat severe cases of AD involving many body sites, it can be time-consuming as patients typically have to receive treatment 2 to 3 times a

week at a dermatology office (though home phototherapy units can improve convenience). The workgroup conditionally recommended phototherapy due to low-certainty evidence (Table III).

A Cochrane systematic review conducted in 2021 was updated to identify new pediatric-specific evidence.⁹⁷ The review identified 9 studies including children, adolescents, and adults. However, pediatric-specific data were not reported in any of the studies. An additional pediatric split-body study of 12 patients with AD compared narrowband ultraviolet B (NB-UVB) combined with 1% pimecrolimus cream to 1% pimecrolimus cream alone—the side treated with NB-UVB and pimecrolimus had a mean reduction of 56% in EASI vs 54% with pimecrolimus alone; risk of bias for this study was moderate due to minimal methods, analysis, and outcome reporting.⁹⁶

We conditionally recommend against PUVA because, while evidence is not available, the safety risks are higher and include various skin cancers, particularly squamous cell carcinoma (Table III). This recommendation applies only to UVA combined with a psoralen-based treatment and is not a recommendation against UVA light alone.

SYSTEMIC THERAPIES

For children and adolescents for whom optimal topical management is insufficient to achieve AD control or who have more severe, widespread AD, or with substantially impaired QoL, systemic therapies may be required to achieve management goals. Shared decision-making is essential when initiating these advanced therapies, considering the severity of AD, its impact on the patient and their caregiver(s), and the efficacy, safety, and accessibility of the interventions. While some systemic AD clinical trials do not allow for the use of topical therapies, in clinical practice it is common to employ topical treatments concomitantly with systemic agents.

Monoclonal antibodies

Over the last 5 years, monoclonal antibodies (biologics) have changed the landscape of pediatric AD treatment. They are effective in severe cases, refractory to optimized topical therapies, and are safe with few side effects. Dupilumab, which blocks the IL-4 receptor alpha subunit and inhibits signaling from IL-4 and IL-13, was the first to gain approval, followed by tralokinumab and lebrikizumab, both IL-13 blockers, and nemolizumab an IL-31 receptor blocker. Omalizumab, an IgE antibody, was also studied in pediatric patients with AD with mixed results, and does not have FDA approval for AD.¹⁵⁶

Dupilumab. The workgroup recommends dupilumab for children 6 months and older with moderate-to-severe AD (Table III). There are less efficacy and safety data on children aged 6 months to under 2 years than for older age groups. Shared decision-making with caregivers and adequate use of topicals is particularly important for all systemic therapies in this very young population. Dosing is tiered by weight and age, but consideration should be given to spacing the doses to every 4 weeks during childhood given the trauma of injection (Table IV). Moreover, efficacy data were relatively equivalent comparing 300 mg every 4 weeks and 200 mg every 2 weeks in children 30–60 kg; the European Medicines Agency recommends dosing for this group at 300 mg every 4 weeks rather than the FDA-recommended 200 mg every 2 weeks.

In adolescents (12–18 years of age) with AD, dupilumab resulted in significantly more patients with IGA 0 or 1 and a clinically meaningful reduction in the SCORAD at 16 weeks (while placebo did not) (Supplementary Table XXVIII, available via Mendeley at <https://data.mendeley.com/datasets/fc2965fjb2/1>).¹⁰¹ Furthermore, dupilumab resulted in significant itch improvement, POEM reduction, fewer flares, and improved QoL. Serious treatment-emergent AEs do not appear to be greater with dupilumab than placebo and withdrawals due to AEs were rare and similar across treatment arms. Conjunctivitis, a well-known potential AE of dupilumab, occurred in 9.8% of dupilumab patients vs 4.7% of placebo patients. Similar findings were described in patients 6 to 11 years of age with severe AD inadequately controlled with topical therapies; in this RCT, both groups were allowed to use topical steroids as needed (Supplementary Table XXIX, available via Mendeley at <https://data.mendeley.com/datasets/fc2965fjb2/1>).⁹⁹ Data for children aged 6 months to 6 years with moderate-to-severe AD was also similar to the data for adolescents in terms of IGA 0 or 1 achievement (RR 7.30 [95% CI: 2.28–23.35]), QoL improvement, and SCORAD, itch, POEM, and flare reduction (Supplementary Table XXX, available via Mendeley at <https://data.mendeley.com/datasets/fc2965fjb2/1>).¹⁰⁰ More importantly, in this vulnerable age group, treatment-related severe/serious AEs and withdrawals due to AEs were equivalent to standard care. Uncontrolled extension data in adolescents over 52 weeks continues to demonstrate effectiveness and safety.⁹⁸

Tralokinumab. An RCT of 182 adolescent patients with AD with TCS/TCI treatment failure demonstrated significant improvement compared to placebo in EASI, IGA, and SCORAD with

tralokinumab (Supplementary Table XXXI, available via Mendeley at <https://data.mendeley.com/datasets/fc2965fjb2/1>). Patients in the treatment group had better QoL outcomes and fewer SAEs.¹⁰² There were no withdrawals in either arm. Extension data to 52 weeks continued to demonstrate effectiveness (EASI 75: 37/70 [52.9%]) and safety.

Lebrikizumab. In 2 RCTs that included 102 adolescents (aged 12 to 18 years) with moderate-to-severe AD, lebrikizumab had positive effects on IGA 0 or 1, EASI 75, and pruritus improvement.¹⁰³ Non-randomized cohort data demonstrated a clinically meaningful improvement in QoL, long-term safety and tolerability, and robust long-term (52-week) efficacy (Supplementary Table XXXII, available via Mendeley at <https://data.mendeley.com/datasets/fc2965fjb2/1>).¹⁰⁴ Combined with topical steroids, lebrikizumab may result in even higher proportions of IGA 0 or 1 and EASI 75 responses, with similar pruritus improvement¹⁰³; but limited QoL difference compared to TCS alone (Supplementary Table XXXIII, available via Mendeley at <https://data.mendeley.com/datasets/fc2965fjb2/1>).¹⁰⁵

Nemolizumab. Two trials, including 266 adolescents (12 years and over) with moderate-to-severe AD, evaluated the efficacy and safety of nemolizumab every 4 weeks compared to placebo, both administered with TCS and with or without TCIs. Nemolizumab and concomitant topical therapy significantly increased the number of adolescents achieving meaningful itch reduction, EASI 75, and IGA success, with little to no difference in rates of serious AEs or discontinuation (Supplementary Table XXXIV, available via Mendeley at <https://data.mendeley.com/datasets/fc2965fjb2/1>).¹⁰⁶ A small trial of 89 children aged 6 to 12 years compared nemolizumab every 4 weeks to placebo, both in combination with TCS, TCIs, or systemic antihistamines. In this trial, nemolizumab resulted in a significant increase in the number of children achieving meaningful itch improvement, IGA success, and at least a 2.5 point improvement in CDLQI, with little to no difference in the number of serious AEs or discontinuation (Supplementary Table XXXV, available via Mendeley at <https://data.mendeley.com/datasets/fc2965fjb2/1>).¹⁰⁷

Omalizumab. FDA-approved for chronic idiopathic urticaria in patients 12 years and older, omalizumab does not have FDA approval for AD treatment. The workgroup did not give a recommendation for this treatment due to insufficient evidence (Supplementary Table XXXVI, available via Mendeley at <https://data.mendeley.com/datasets/fc2965fjb2/1>). In a trial of 60 adolescent

(12-19 year old) patients with AD, omalizumab resulted in a clinically meaningful reduction in EASI, but the impact on other outcome measures (e.g. POEM score, flares, Children's Dermatology Life Quality Index [CDLQI]) was less clear but probably favorable.¹⁵⁶ Rates of AEs and withdrawal were equitable across treatment arms. While the single RCT suggests benefit, there are well-known risks of therapy that need to be considered, particularly allergic reactions to the medication early in the course. Additionally, the totality of available evidence on the use of omalizumab for AD suggests no clear benefit.^{157,158}

JAK inhibitors

JAK inhibitors are another systemic option for AD. Effective in other disciplines, including oncology and rheumatology, they are used to treat severe alopecia areata, psoriasis, AD, and other skin conditions. As mentioned previously with topical ruxolitinib, JAKis carry several black box safety warnings. While evidence to date is reassuring for their safety in otherwise healthy dermatology patients, including children, caution is recommended when using these medications, including appropriate laboratory monitoring.

Of the systemic JAKis, upadacitinib and abrocitinib have FDA approval for AD in patients as young as 12 years of age who have failed other systemic therapies or when use of those therapies is inadvisable. "Failure" as it appears in the recommendation is not simply an inadequate therapeutic response but also encapsulates intolerable side effects, among other considerations. Systemic JAKis come in oral form, which needle-phobic patients may prefer to monoclonal antibody treatments, even though laboratory testing is indicated in product labels for JAKis.

Abrocitinib. In a RCT including 50 adolescents with moderate-to-severe AD, 43.8% receiving abrocitinib vs 0% receiving placebo achieved EASI 75, and 12.5% receiving abrocitinib vs 0% receiving placebo achieved IGA 0 or 1 response and a ≥ 2 grade improvement from baseline (Supplementary Table XXXVII, available via Mendeley at <https://data.mendeley.com/datasets/fc2965fjb2/1>).¹¹⁶ In 2 other RCTs, abrocitinib resulted in an improvement in POEM, itch, and QoL.¹¹³ Combining abrocitinib with prescription topical treatments results in similarly positive outcomes and a favorable safety profile (Supplementary Table XXXVIII, available via Mendeley at <https://data.mendeley.com/datasets/fc2965fjb2/1>).¹¹⁷ A safety analysis including adults and adolescents found people who were given abrocitinib were more likely to report nausea, headache, and acne than people given placebo.

These AEs were typically mild or moderate and did not result in discontinuation of treatment.¹¹⁵ Herpes simplex infection was more common in people taking abrocitinib (4/100 participants for 200 mg and about 3/100 participants for 100 mg) than in people who took placebo (2/100 participants); herpes zoster may also occur more frequently in those on abrocitinib.

Baricitinib. Baricitinib is not FDA-approved for use in AD, but it is approved for AD in children ≥ 2 years old in Europe and the workgroup recommends its use based on moderate certainty evidence (Supplementary Tables XXXIX–XL, available via Mendeley at <https://data.mendeley.com/datasets/fc2965fjb2/1>). In the primary RCT of 242 moderate-to-severe patients with AD aged 2–17 years, both the 2 mg daily and 4 mg daily dosing schedules were effective, but the 4 mg dose resulted in a higher proportion of patients achieving vIGA-AD 0–1 and meaningful reductions in EASI score.¹¹⁸ With both doses, serious AEs and withdrawal due to AEs were low.

Upadacitinib. Like the previously mentioned systemic JAKis, upadacitinib was also shown to be effective in adolescents with AD (Supplementary Tables XLI–XLII, available via Mendeley at <https://data.mendeley.com/datasets/fc2965fjb2/1>). In 2 RCTs including 177 adolescent patients, percent reduction in EASI from baseline was -23.9 with placebo vs -77.3 with upadacitinib.¹⁰⁸ Furthermore, significantly more patients had meaningful itch reduction (numeric rating scale score ≥ 4) and CDLQI reduction. Another RCT of adolescent patients with AD comparing upadacitinib in combination with TCS compared to placebo with TCS described similar findings.¹¹² Serious AEs and withdrawal due to AEs were low. The most common treatment-emergent AEs were acne (11.5% vs 2.5%), headache (6.6% vs 3.3%), upper respiratory tract infections (9% vs 5%), creatine phosphokinase level elevations (6.6% vs 2.5%) and nasopharyngitis (4.1% vs 2.5%).¹⁰⁹ However, treatment-emergent AEs of interest were infrequent with no significant difference between groups in terms of serious infection; no opportunistic infections, active tuberculosis, malignant neoplasms (including nonmelanoma skin cancer), or any adjudicated major adverse cardiac events, venous thromboembolisms, or events of gastrointestinal perforation were reported in adolescents. This favorable AE profile was also described in another RCT studying upadacitinib in combination with TCS.¹¹⁰ Extension data at 112 weeks demonstrated sustained efficacy and found no new safety signals, though absolute numbers were small (19 patients).¹¹¹ Of note, the FDA approved a starting

dose of 15 mg daily, but stated that the dose can be increased to 30 mg daily if there is an inadequate response; based on the available data, we feel that 4–12 weeks is an appropriate time to assess response.

Antimetabolites

Methotrexate. Though it does not have FDA approval, before the emergence of monoclonal antibodies and JAKis, methotrexate was used more commonly to control moderate-to-severe AD. It is still an effective option, but comorbidities or drug interactions that may exacerbate toxicity render it inappropriate for select patients.

In a small RCT of children aged 8–14 years with severe AD comparing methotrexate 7.5 mg weekly (initial dose of 5 mg) to cyclosporine 2.5 mg/kg/day for 12 weeks, both treatments resulted in meaningful SCORAD reductions (Supplementary Table XLIII, available via Mendeley at <https://data.mendeley.com/datasets/fc2965fjb2/1>).¹⁵⁹ However, methotrexate showed a later relapse than cyclosporine (20 weeks vs 14 weeks on average). Both medications appeared to be safe with no withdrawals. In a similar RCT comparing high-dose cyclosporine (up to 5 mg/kg/day) to methotrexate (0.4 mg/kg weekly – maximum dose of 25 mg weekly) for 36 weeks, high-dose cyclosporine resulted in a higher proportion of patients achieving EASI 50 at 12 weeks but a lower proportion by 36 weeks (Supplementary Table XLIV, available via Mendeley at <https://data.mendeley.com/datasets/fc2965fjb2/1>).¹¹⁹ Both treatments were similar in terms of POEM scores, flares (though methotrexate performed better), and CDLQI. Serious AEs and withdrawal due to AEs were similar between groups. Given the well-known risks of methotrexate, it is advisable to conduct conservative laboratory monitoring, particularly to look for hepatic and hematologic AEs.

Immunosuppressants

Systemic corticosteroids. The workgroup's good practice statement against systemic corticosteroids as a long-term treatment for AD is based on a body of indirect evidence on the harms of systemic steroids in other inflammatory skin diseases and adults (Supplementary Table XLV, available via Mendeley at <https://data.mendeley.com/datasets/fc2965fjb2/1>).¹⁶⁰ Efficacy data were very low certainty (ie no direct RCTs), but the certainty of the harms data is higher. The harms are of particular concern in the pediatric population due to their significant impact on growth and bone formation.

Schmitt et al compared prednisolone (0.5–0.8 mg/kg tapered to 0 over 2 weeks) to cyclosporine (2.7–4.0 mg/kg/day for 6 weeks) in adults with severe

AD.¹²⁹ Both treatments resulted in clinically meaningful reductions in SCORAD at 6 weeks, but the trial stopped early due to safety issues based on the high rate of relapse in the prednisolone group; as a result, treatment discontinuation was common in both arms but higher with prednisolone due to the high rate of relapse.

The use of systemic steroids should be reserved exclusively for acute, severe exacerbations as a short-term bridge therapy to other steroid-sparing treatments. Systemic steroids have no role in long-term maintenance treatment for AD, particularly in children.

Mycophenolate mofetil. There was no direct evidence for the use of mycophenolate mofetil (MMF) in the management of children or adolescents with AD (Supplementary Table XLVI, available via Mendeley at <https://data.mendeley.com/datasets/fc2965fjb2/1>). A conditional recommendation with proper monitoring was given despite a lack of FDA approval and scant data, as MMF can be a safe and effective treatment in certain severe AD cases (Table III). Nonetheless, comorbidities or drug interactions that may exacerbate toxicity make this intervention inappropriate for select patients.

A non-inferiority trial in adults with severe AD comparing enteric-coated mycophenolate sodium 1440 mg/day to cyclosporine A 3 mg/kg/day as maintenance therapy after a 6-week run-in phase of cyclosporine A 5 mg/kg/day found SCORAD scores remained comparable at 10 and 33 weeks with no SAEs reported in either arm.¹²¹ The authors concluded that mycophenolate sodium was as effective as cyclosporine A for maintenance therapy. A systematic review and meta-analysis of individual patient data reported that for patients with refractory AD (mean age 38.21 ± 22.8) there was a statistically significant reduction in SCORAD scores after MMF treatment: Mean difference 18.01 (95% CI: 8.54, 27.48, $P = .0002$; $n = 37$).¹²² Across the 140 patients included in the review, MMF was effective (complete or partial remission) in 77% with relapses occurring in 8.2%. The most common AEs reported were headaches (10.7%), gastric discomfort (10.7%), herpes infection (9.3%), deranged liver function tests (7.9%), and other infections (6.4%).

Azathioprine. As with MMF, the workgroup gave a conditional recommendation for azathioprine but only for limited-term use and with proper monitoring and prescreening of thiopurine methyltransferase activity to ensure safety (Table III). The evidence is sparse and of high risk of bias due to limited methods reporting and selective outcome reporting (Supplementary Table XLVII, available via Mendeley at <https://data.mendeley.com/datasets/fc2965fjb2/1>).

Furthermore, the study sample (adolescents and adults aged 16 years and over) differs from the population of interest, but the data suggest an improvement in 6 Area, 6 Sign Atopic Dermatitis Severity score, itch, and Dermatology Life Quality Index.

Cyclosporine. While it is not FDA approved for use in pediatric AD, cyclosporine is approved by the European Medicines Agency for severe AD in individuals 1 year of age and older. We recommend it conditionally for limited-term use with proper monitoring (Table III).

Cyclosporine was already discussed above in trials comparing it to methotrexate. No direct evidence was identified to assess the management of AD in children or adolescents with cyclosporine (Supplementary Table XLVIII, available via Mendeley at <https://data.mendeley.com/datasets/fc2965fjb2/1>). In adults, cyclosporine was shown to be superior to phototherapy,¹²⁶ oral prednisolone¹²⁹ and similar to methotrexate¹²⁵ and extracorporeal photopheresis.¹²⁷

Systemics with insufficient evidence

The following systemic agents had insufficient evidence to make a recommendation regarding the treatment of pediatric AD: intravenous immunoglobulin, interferon gamma, systemic calcineurin inhibitors (other than cyclosporine), systemic antibiotics, oral antihistamines, and systemic antivirals for eczema herpeticum (Supplementary Tables XLIX–LI, available via Mendeley at <https://data.mendeley.com/datasets/fc2965fjb2/1>). However, if recommended options are ineffective, they could be considered. See Supplementary Appendix 2, available via Mendeley at <https://data.mendeley.com/datasets/fc2965fjb2/1> for assessments of the evidence related to each of the interventions above.

Cost

Assessing the certainty of the best available evidence for net therapeutic benefit and consideration of patient values and preferences are the primary drivers of recommendation development in AAD guidelines. However, the workgroup recognizes that costs for some recommended therapies may be prohibitive without adequate insurance coverage. Cost should be considered during the shared decision-making process.

Gaps in research

While there is no shortage of studies describing the efficacy of moisturization in AD, we still do not know the optimal ingredients and formulations. A recent study comparing 4 different types of

emollients in children with AD found no difference in effectiveness between the groups, which may indicate (for now) that using any type of moisturizer may be helpful.¹⁶¹ Furthermore, there are unanswered questions when it comes to wet dressings (and how to optimally utilize them), as well as bathing.

From a therapeutic standpoint, there are more treatments for patients with AD than ever before. At the time of this publication, for example, there are 5 non-steroidal topical agents for AD. However, many of these new medications are costly and access can be challenging. More head-to-head studies comparing new medications to older generic TCS in terms of efficacy and safety are needed. Furthermore, more pediatric-specific data, particularly for older agents, will also be helpful for providers when they are making therapeutic decisions for their patients. With a variety of biologics and oral JAKis available, it is easy to overlook cheaper yet effective immunosuppressive agents and NB-UVB phototherapy. It would be useful to have studies examining these agents and how they compare with newer agents in the pediatric population. Many studies of older agents are specific to adults or at least not exclusive to children, making recommendations specific to children more challenging.

CONCLUSIONS

We provide 27 evidence-based recommendations on the medical management of AD in pediatric patients. We make strong recommendations for the use of moisturizers, topical calcineurin inhibitors, topical corticosteroids, crisaborole ointment, roflumilast cream, ruxolitinib cream, tapinarof cream, dupilumab, tralokinumab, lebrikizumab, nemolizumab with concomitant topical therapy, upadacitinib, abrocitinib, and baricitinib in the treatment of pediatric AD. Conditional recommendations were made in favor of bathing, bleach baths, wet dressings, phototherapy, methotrexate, mycophenolate mofetil, azathioprine, and cyclosporine. We conditionally recommend against the use of topical antimicrobials, PUVA phototherapy, and strongly recommend against long term use of systemic corticosteroids.

Declaration of generative AI and AI-assisted technologies in the writing process

Not used in the preparation of this manuscript.

Conflicts of interest

Drs Alikhan, Bercovitch, Davis, Frazer-Green, and Jennifer M. Darr, LCSW, have no relationships to disclose.

Cohen serves on the board of directors for Timber and Evomune receiving stock options and/or fees; as a consultant for Asana Biosciences, Ferndale Laboratories, Inc., Novartis, Facilitation of International Dermatology Education, Dermavant Sciences, Leo Pharma, Inc., UCB, and Cosmetic Ingredient Review receiving honoraria and/or stock options. Drucker receives research grants paid to his institution from the National Eczema Association, Eczema Society of Canada, Canadian Dermatology Foundation, Canadian Institutes for Health Research, US National Institutes of Health, and Physician Services Incorporated Foundation. Eichenfield serves on the board of directors for Forte Biosciences and Verrica Pharmaceuticals, Inc., receiving honoraria and/or stock options; as an investigator for Abbvie, Arcutis, Dermavant, Galderma Laboratories, Pfizer and Bausch, receiving research grants, fees and/or honoraria; as a consultant for Abbvie, Almirall, Arcutis, Asana, Dermavant, Eli Lilly, Galderma, Ichnos/Glenmark, Incyte, Janssen, Leo Pharma, Novartis, Ortho Dermatologics, Otsuka, Pfizer, Regeneron, and Sanofi Genzyme, honoraria; as an independent contractor for Elsevier, Inc. receiving royalties. Paller serves as a consultant for Abeona, Arcutis, BioCryst, Boehringer-Ingelheim, Castle Creek, Chiesi, Dermavant, Johnson & Johnson Innovative Medicine, Krystal, LEO, Lilly, L'Oreal, MoonLake Immunotherapeutics, Peltheos, Quoin, Regeneron, and Sanofi receiving honoraria; on a data safety monitoring board for AbbVie, Abeona, Biocryst, Daiichi Sankyo, and Galderma receiving compensation; and as an investigator for AbbVie, Biomendics, Dermavant, Eli Lilly, Incyte, Johnson & Johnson Innovative Medicine, Regeneron, and UCB receiving no compensation. Schwarzenberger is the founder of Pretel, Inc. and serves as a data safety monitoring board member for Pfizer, Inc. receiving fees. Sidbury serves as an advisory board member for Pfizer, Inc. receiving honoraria; as a principal investigator for Regeneron receiving grants and research funding; as an investigator for Brickell Biotech, Inc., and Galderma USA receiving grants and research funding; as a consultant for Galderma Global and Microes receiving fees or no compensation. Silverberg serves as an advisory board member for BioMX, Boehringer Ingelheim, RAPT Therapeutics, Celgene, Ortho Dermatologics, TARGET Pharma, AFYX Therapeutics, Corrona, Inc., Dermira, Pfizer, Inc., Leo Pharma, Inc, and Menlo Therapeutics receiving honoraria and/or fees; as an investigator for DS Pharma, TARGET Pharma, Kiniksa Pharmaceuticals, Ltd, Menlo Therapeutics, GlaxoSmithKline, AbbVie, Leo Pharma, Inc, and Regeneron receiving research funding, honoraria, or no compensation; as a consultant for AOBiome, Bluefin Biomedicine, Bodewell, BiomX, Inc, Galderma Research & Development, LLC, Arena Pharmaceuticals, Dermavant Sciences, Incyte Corporation, DS Biopharma, Sun Pharmaceutical Industries, Ltd, AnaptysBio, Asana Biosciences, LLC, Pfizer, Inc., Glenmark Generics, Inc, Sanofi, Kiniksa Pharmaceuticals, Ltd, GlaxoSmithKline, Eli Lilly and Company, AbbVie, Regeneron, and Medimmune receiving honoraria or fees; as a speaker for the Fall Clinical

Dermatology Conference, Maui Derm, and Regeneron receiving honoraria or fees. Singh as an advisory board member for Incyte receiving honoraria. Peggy Wu, MD, MPH is an author for UpToDate, Inc receiving honoraria.

REFERENCES

1. Davis DMR, Drucker AM, Alikhan A, et al. Guidelines of care for the management of atopic dermatitis in adults with phototherapy and systemic therapies. *J Am Acad Dermatol*. 2024;90(2):e43-e56. <https://doi.org/10.1016/j.jaad.2023.08.102>
2. Sidbury R, Alikhan A, Bercovitch L, et al. Guidelines of care for the management of atopic dermatitis in adults with topical therapies. *J Am Acad Dermatol*. 2023;89(1):e1-e20. <https://doi.org/10.1016/j.jaad.2022.12.029>
3. Eichenfield LF, Tom WL, Berger TG, et al. Guidelines of care for the management of atopic dermatitis: section 2. Management and treatment of atopic dermatitis with topical therapies. *J Am Acad Dermatol*. 2014;71(1):116-132. <https://doi.org/10.1016/j.jaad.2014.03.023>
4. Eichenfield LF, Tom WL, Chamlin SL, et al. Guidelines of care for the management of atopic dermatitis: section 1. Diagnosis and assessment of atopic dermatitis. *J Am Acad Dermatol*. 2014;70(2):338-351. <https://doi.org/10.1016/j.jaad.2013.10.010>
5. Sidbury R, Davis DM, Cohen DE, et al. Guidelines of care for the management of atopic dermatitis: section 3. Management and treatment with phototherapy and systemic agents. *J Am Acad Dermatol*. 2014;71(2):327-349. <https://doi.org/10.1016/j.jaad.2014.03.030>
6. Sidbury R, Tom WL, Bergman JN, et al. Guidelines of care for the management of atopic dermatitis: section 4. Prevention of disease flares and use of adjunctive therapies and approaches. *J Am Acad Dermatol*. 2014;71(6):1218-1233. <https://doi.org/10.1016/j.jaad.2014.08.038>
7. Andrews J, Guyatt G, Oxman AD, et al. GRADE guidelines: 14. Going from evidence to recommendations: the significance and presentation of recommendations. *J Clin Epidemiol*. 2013;66(7):719-725. <https://doi.org/10.1016/j.jclinepi.2012.03.013>
8. Andrews JC, Schunemann HJ, Oxman AD, et al. GRADE guidelines: 15. Going from evidence to recommendation—determinants of a recommendation's direction and strength. *J Clin Epidemiol*. 2013;66(7):726-735. <https://doi.org/10.1016/j.jclinepi.2013.02.003>
9. Guyatt GH, Alonso-Coello P, Schunemann HJ, et al. Guideline panels should seldom make good practice statements: guidance from the GRADE Working Group. *J Clin Epidemiol*. 2016;80:3-7. <https://doi.org/10.1016/j.jclinepi.2016.07.006>
10. Bakaa L, Pernica JM, Couban RJ, et al. Bleach baths for atopic dermatitis: a systematic review and meta-analysis including unpublished data, Bayesian interpretation, and GRADE. *Ann Allergy Asthma Immunol*. 2022;128(6):660-668.e9. <https://doi.org/10.1016/j.anai.2022.03.024>
11. Chu DK, Chu AWL, Rayner DG, et al. Topical treatments for atopic dermatitis (eczema): systematic review and network meta-analysis of randomized trials. *J Allergy Clin Immunol*. 2023;152(6):1493-1519. <https://doi.org/10.1016/j.jaci.2023.08.030>
12. Lax SJ, Van Vogt E, Candy B, et al. Topical anti-inflammatory treatments for eczema: a cochrane systematic review and network meta-analysis. *Clin Exp Allergy*. 2024;54(12):960-972. <https://doi.org/10.1111/cea.14556>
13. Drucker AM, Lam M, Prieto-Merino D, et al. Systemic immunomodulatory treatments for atopic dermatitis: living systematic review and network meta-analysis update. *JAMA Dermatol*. 2024;160(9):936-944. <https://doi.org/10.1001/jama.dermatol.2024.2192>
14. Alexopoulos A, Dakoutrou M, Nasi L, et al. A randomized, observer-blind, vehicle-control, multi-center clinical investigation for assessing the efficacy and tolerability of a 1% ectoine and hyaluronic acid 0.1%-containing medical device in pediatric patients with mild-to-moderate atopic dermatitis. *Pediatr Dermatol*. 2023;40(1):78-83. <https://doi.org/10.1111/pde.15117>
15. Bianchi P, Theunis J, Casas C, et al. Effects of a new emollient-based treatment on skin microflora balance and barrier function in children with mild atopic dermatitis. *Pediatr Dermatol*. 2016;33(2):165-171. <https://doi.org/10.1111/pde.12786>
16. Boguniewicz M, Zeichner JA, Eichenfield LF, et al. MAS063DP is effective monotherapy for mild to moderate atopic dermatitis in infants and children: a multicenter, randomized, vehicle-controlled study. *J Pediatr*. 2008;152(6):854-859. <https://doi.org/10.1016/j.jpeds.2007.11.031>
17. Boralevi F, Saint Aroman M, Delarue A, et al. Long-term emollient therapy improves xerosis in children with atopic dermatitis. *J Eur Acad Dermatol Venereol*. 2014;28(11):1456-1462. <https://doi.org/10.1111/jdv.12314>
18. De Belilovsky C, Roo-Rodriguez E, Baudouin C, Menu F, Chadoutaud B, Msika P. Natural peroxisome proliferator-activated receptor- α agonist cream demonstrates similar therapeutic response to topical steroids in atopic dermatitis. *J Dermatolog Treat*. 2011;22(6):359-365. <https://doi.org/10.3109/09546634.2010.499932>
19. Draelos ZD, Traub M, Gold MH, et al. Efficacy of topical botanical treatment of children with mild to moderate atopic dermatitis. *J Drugs Dermatol*. 2019;18(10):1038-1045.
20. Gayraud F, Sayag M, Jourdan E. Efficacy and tolerance assessment of a new type of dermocosmetic in infants and children with moderate atopic dermatitis. *J Cosmet Dermatol*. 2015;14(2):107-112. <https://doi.org/10.1111/jocd.12145>
21. Giordano-Labadie F, Cambazard F, Guillet G, Combemale P, Meneaud V. Evaluation of a new moisturizer (Exomega milk) in children with atopic dermatitis. *J Dermatolog Treat*. 2006;17(2):78-81. <https://doi.org/10.1080/09546630600552216>
22. Grimalt R, Meneaud V, Cambazard F. The steroid-sparing effect of an emollient therapy in infants with atopic dermatitis: a randomized controlled study. *Dermatology*. 2007;214(1):61-67. <https://doi.org/10.1159/000096915>
23. Horev A, Sher M, Weissmann S, Golan L, Horev A. Medihoney derma cream treatment for mild to moderate atopic dermatitis in children: an open-label randomized pilot study. *Dermatitis*. 2022;33(6s):S147-S149. <https://doi.org/10.1097/der.0000000000000913>
24. Jirabundansuk P, Ophaswongse S, Udompataikul M. Comparative trial of moisturizer containing spent grain wax, Butyrospermum parkii extract, Argania spinosa kernel oil vs. 1% hydrocortisone cream in the treatment of childhood atopic dermatitis. *J Med Assoc Thai*. 2014;97(8):820-826.
25. Korting H, Schöllmann C, Cholcha W, Wolff L, Group TCS. Efficacy and tolerability of pale sulfonated shale oil cream 4% in the treatment of mild to moderate atopic eczema in children: a multicentre, randomized vehicle-controlled trial. *J Eur Acad Dermatol Venereol*. 2010;24(10):1176-1182. <https://doi.org/10.1111/j.1468-3083.2010.03616.x>

26. Liu L, Ong G. A randomized, open-label study to evaluate an intermittent dosing regimen of fluticasone propionate 0.05% cream in combination with regular emollient skin care in reducing the risk of relapse in pediatric patients with stabilized atopic dermatitis. *J Dermatolog Treat*. 2018;29(5):501-509. <https://doi.org/10.1080/09546634.2017.1401211>
27. Lucky AW, Leach AD, Laskarzewski P, Wenck H. Use of an emollient as a steroid-sparing agent in the treatment of mild to moderate atopic dermatitis in children. *Pediatr Dermatol*. 1997;14(4):321-324. <https://doi.org/10.1111/j.1525-1470.1997.tb00968.x>
28. Ma L, Li P, Tang J, et al. Prolonging time to flare in pediatric atopic dermatitis: a randomized, investigator-blinded, controlled, multicenter clinical study of a ceramide-containing moisturizer. *Adv Ther*. 2017;34(12):2601-2611. <https://doi.org/10.1007/s12325-017-0640-6>
29. Msika P, De Belilovsky C, Piccardi N, Chebassier N, Baudouin C, Chadoutaud B. New emollient with topical corticosteroid-sparing effect in treatment of childhood atopic dermatitis: SCORAD and quality of life improvement. *Pediatr Dermatol*. 2008;25(6):606-612. <https://doi.org/10.1111/j.1525-1470.2008.00783.x>
30. Patrizi A, Capitanio B, Neri I, et al. A double-blind, randomized, vehicle-controlled clinical study to evaluate the efficacy and safety of MAS063DP (ATOPICLAIR) in the management of atopic dermatitis in paediatric patients. *Pediatr Allergy Immunol*. 2008;19(7):619-625. <https://doi.org/10.1111/j.1399-3038.2008.00724.x>
31. Sivapiromrat P, Kamanamool N, Udompataikul M. The comparative efficacy between shea butter-ceramide cream and 1% hydrocortisone cream in childhood atopic dermatitis. Chotmaihet thangphaet *J Med Assoc Thai*. 2021;104(7):1172-1178. <https://doi.org/10.35755/jmedassocthai.2021.07.12669>
32. Sugarman JL, Parish LC. Efficacy of a lipid-based barrier repair formulation in moderate-to-severe pediatric atopic dermatitis. *J Drugs Dermatol*. 2009;8(12):1106-1111.
33. Tiplica GS, Boralevi F, Konno P, et al. The regular use of an emollient improves symptoms of atopic dermatitis in children: a randomized controlled study. *J Eur Acad Dermatol Venereol*. 2018;32(7):1180-1187. <https://doi.org/10.1111/jdv.14849>
34. Tripodi S, Di Rienzo Businco A, Panetta V, et al. Lack of efficacy of topical furfuryl palmitate in pediatric atopic dermatitis: a randomized double-blind study. *J Investig Allergol Clin Immunol*. 2009;19(3):204-209.
35. Udompataikul M, Srisatwaja W. Comparative trial of moisturizer containing licochalcone A vs. hydrocortisone lotion in the treatment of childhood atopic dermatitis: a pilot study. *J Eur Acad Dermatol Venereol*. 2011;25(6):660-665. <https://doi.org/10.1111/j.1468-3083.2010.03845.x>
36. Wananukul S, Chatproedprai S, Chunharas A, et al. Randomized, double-blind, split-side, comparison study of moisturizer containing licochalcone A and 1% hydrocortisone in the treatment of childhood atopic dermatitis. *J Med Assoc Thai*. 2013;96(9):1135-1142.
37. Wang S, Wang L, Li P, et al. The improvement of infantile atopic dermatitis during the maintenance period: a multicenter, randomized, parallel controlled clinical study of emollients in *Prinsepia utilis* Royle. *Dermatol Ther*. 2020;33(2):e13153. <https://doi.org/10.1111/dth.13153>
38. Weber TM, Samarin F, Babcock MJ, Filbry A, Rippke F. Steroid-free over-the-counter eczema skin care formulations reduce risk of flare, prolong time to flare, and reduce eczema symptoms in pediatric subjects with atopic dermatitis. *J Drugs Dermatol*. 2015;14(5):478-485.
39. Cardona ID, Kempe EE, Lary C, Ginder JH, Jain N. Frequent versus infrequent bathing in pediatric atopic dermatitis: a randomized clinical trial. *J Allergy Clin Immunol Pract*. 2020;8(3):1014-1021. <https://doi.org/10.1016/j.jaip.2019.10.042>
40. Inuzuka Y, Natsume O, Matsunaga M, et al. Washing with water alone versus soap in maintaining remission of eczema. *Pediatr Int*. 2020;62(6):663-668. <https://doi.org/10.1111/ped.14216>
41. Koutroulis I, Petrova K, Kratimenos P, Gaughan J. Frequency of bathing in the management of atopic dermatitis: to bathe or not to bathe? *Clin Pediatr (Phila)*. 2014;53(7):677-681. <https://doi.org/10.1177/0009922814526980>
42. Santer M, Ridd MJ, Francis NA, et al. Emollient bath additives for the treatment of childhood eczema (BATHE): multicentre pragmatic parallel group randomised controlled trial of clinical and cost effectiveness. *BMJ*. 2018;361:k1332. <https://doi.org/10.1136/bmj.k1332>
43. Hindley D, Galloway G, Murray J, Gardener L. A randomised study of "wet wraps" versus conventional treatment for atopic eczema. *Arch Dis Child*. 2006;91(2):164-168. <https://doi.org/10.1136/adc.2004.050831>
44. Wong AW, Hon EK, Zee B. Is topical antimycotic treatment useful as adjuvant therapy for flexural atopic dermatitis: randomized, double-blind, controlled trial using one side of the elbow or knee as a control. *Int J Dermatol*. 2008;47(2):187-191. <https://doi.org/10.1111/j.1365-4632.2008.03414.x>
45. Boguniewicz M, Fiedler VC, Raimer S, Lawrence ID, Leung DY, Hanifin JM. A randomized, vehicle-controlled trial of tacrolimus ointment for treatment of atopic dermatitis in children. Pediatric Tacrolimus Study Group. *J Allergy Clin Immunol*. 1998;102(4 Pt 1):637-644. [https://doi.org/10.1016/s0091-6749\(98\)70281-7](https://doi.org/10.1016/s0091-6749(98)70281-7)
46. Chapman MS, Schachner LA, Breneman D, et al. Tacrolimus ointment 0.03% shows efficacy and safety in pediatric and adult patients with mild to moderate atopic dermatitis. *J Am Acad Dermatol*. 2005;53(2 Suppl 2):S177-S185. <https://doi.org/10.1016/j.jaad.2005.04.061>
47. Devasenapathy N, Chu A, Wong M, et al. Cancer risk with topical calcineurin inhibitors, pimecrolimus and tacrolimus, for atopic dermatitis: a systematic review and meta-analysis. *Lancet Child Adolesc Health*. 2023;7(1):13-25. [https://doi.org/10.1016/s2352-4642\(22\)00283-8](https://doi.org/10.1016/s2352-4642(22)00283-8)
48. Paller A, Eichenfield LF, Leung DY, Stewart D, Appell M. A 12-week study of tacrolimus ointment for the treatment of atopic dermatitis in pediatric patients. *J Am Acad Dermatol*. 2001;44(1 Suppl):S47-S57. <https://doi.org/10.1067/mjd.2001.109813>
49. Schachner LA, Lamerson C, Sheehan MP, et al. Tacrolimus ointment 0.03% is safe and effective for the treatment of mild to moderate atopic dermatitis in pediatric patients: results from a randomized, double-blind, vehicle-controlled study. *Pediatrics*. 2005;116(3):e334-e342. <https://doi.org/10.1542/peds.2004-2638>
50. Breuer K, Braeutigam M, Kapp A, Werfel T. Influence of Pimecrolimus cream 1% on different morphological signs of eczema in infants with atopic dermatitis. *Dermatology*. 2004;209(4):314-320. <https://doi.org/10.1159/000080855>
51. Eichenfield LF, Lucky AW, Boguniewicz M, et al. Safety and efficacy of pimecrolimus (ASM 981) cream 1% in the treatment of mild and moderate atopic dermatitis in children and adolescents. *J Am Acad Dermatol*. 2002;46(4):495-504. <https://doi.org/10.1067/mjd.2002.122187>
52. Fowler J, Johnson A, Chen M, Abrams K. Improvement in pruritus in children with atopic dermatitis using pimecrolimus cream 1%. *Cutis*. 2007;79(1):65-72.

53. Ho VC, Gupta A, Kaufmann R, et al. Safety and efficacy of nonsteroid pimecrolimus cream 1% in the treatment of atopic dermatitis in infants. *J Pediatr*. 2003;142(2):155-162. <https://doi.org/10.1067/mpd.2003.65>
54. Hoeger PH, Lee KH, Jautova J, et al. The treatment of facial atopic dermatitis in children who are intolerant of, or dependent on, topical corticosteroids: a randomized, controlled clinical trial. *Br J Dermatol*. 2009;160(2):415-422. <https://doi.org/10.1111/j.1365-2133.2008.08928.x>
55. Kapp A, Papp K, Bingham A, et al. Long-term management of atopic dermatitis in infants with topical pimecrolimus, a nonsteroid anti-inflammatory drug. *J Allergy Clin Immunol*. 2002;110(2):277-284. <https://doi.org/10.1067/mai.2002.126500>
56. Kaufmann R, Fölster-Holst R, Höger P, et al. Onset of action of pimecrolimus cream 1% in the treatment of atopic eczema in infants. *J Allergy Clin Immunol*. 2004;114(5):1183-1188. <https://doi.org/10.1016/j.jaci.2004.08.015>
57. Leo HL, Bender BG, Leung SB, Tran ZV, Leung DY. Effect of pimecrolimus cream 1% on skin condition and sleep disturbance in children with atopic dermatitis. *J Allergy Clin Immunol*. 2004;114(3):691-693. <https://doi.org/10.1016/j.jaci.2004.05.037>
58. NCT00828412. Comparison of the Efficacy and Safety of Two Topical Creams for Pediatric Atopic Dermatitis. 2009.. Accessed January 6, 2026. <https://clinicaltrials.gov/study/NCT00828412>
59. NCT03539601. A Study of Crisaborole Ointment 2%; Crisaborole Vehicle; TCS and TCI in Subjects Aged ≥ 2 Years, With Mild-Moderate AD. 2018.. Accessed January 6, 2026. <https://clinicaltrials.gov/study/NCT03539601>
60. Schneider L, Hanifin J, Boguniewicz M, et al. Study of the atopic March: development of atopic comorbidities. *Pediatr Dermatol*. 2016;33(4):388-398. <https://doi.org/10.1111/pde.12867>
61. Siegfried E, Korman N, Molina C, Kianifard F, Abrams K. Safety and efficacy of early intervention with pimecrolimus cream 1% combined with corticosteroids for major flares in infants and children with atopic dermatitis. *J Dermatolog Treat*. 2006;17(3):143-150. <https://doi.org/10.1080/09546630600647297>
62. Thaçi D, Reitamo S, Gonzalez Ensenat MA, et al. Proactive disease management with 0.03% tacrolimus ointment for children with atopic dermatitis: results of a randomized, multicentre, comparative study. *Br J Dermatol*. 2008;159(6):1348-1356. <https://doi.org/10.1111/j.1365-2133.2008.08813.x>
63. CASM981C1301. Confirmatory Study in Pediatric Patients with Atopic Dermatitis. 2005.. Accessed January 6, 2026. <https://www.novctrd.com/ctrweb/trialresult/trialresults/pdf?trialResultId=1997>
64. Langley RG, Eichenfield LF, Lucky AW, Boguniewicz M, Barbier N, Cherill R. Sustained efficacy and safety of pimecrolimus cream 1% when used long-term (up to 26 weeks) to treat children with atopic dermatitis. *Pediatr Dermatol*. 2008;25(3):301-307. <https://doi.org/10.1111/j.1525-1470.2008.00671.x>
65. Sigurgeirsson B, Ho V, Ferrándiz C, Andriano K, Grinienko A, Jimenez P. Effectiveness and safety of a prevention-of-flare-progression strategy with pimecrolimus cream 1% in the management of paediatric atopic dermatitis. *J Eur Acad Dermatol Venerol*. 2008;22(11):1290-1301. <https://doi.org/10.1111/j.1468-3083.2008.02785.x>
66. Spergel JM, Boguniewicz M, Schneider L, Hanifin JM, Paller AS, Eichenfield LF. Food allergy in infants with atopic dermatitis: limitations of food-specific IgE measurements. *Pediatrics*. 2015;136(6):e1530-e1538. <https://doi.org/10.1542/peds.2015-1444>
67. Wahn U, Bos JD, Goodfield M, et al. Efficacy and safety of pimecrolimus cream in the long-term management of atopic dermatitis in children. *Pediatrics*. 2002;110(1 Pt 1):e2. <https://doi.org/10.1542/peds.110.1.e2>
68. Zuberbier T, Heinzerling L, Bieber T, Schauer U, Klebs S, Bräutigam M. Steroid-sparing effect of pimecrolimus cream 1% in children with severe atopic dermatitis. *Dermatology*. 2007;215(4):325-330. <https://doi.org/10.1159/000107627>
69. Kimball AB, Gold MH, Zib B, Davis MW. Clobetasol propionate emulsion formulation foam 0.05%: review of phase II open-label and phase III randomized controlled trials in steroid-responsive dermatoses in adults and adolescents. *J Am Acad Dermatol*. 2008;59(3):448-454, 454.e1. <https://doi.org/10.1016/j.jaad.2008.04.020>
70. Wu SH, Chen XQ, Liu B, Wu HJ, Dong L. Efficacy and safety of 15(R/S)-methyl-lipoxin A(4) in topical treatment of infantile eczema. *Br J Dermatol*. 2013;168(1):172-178. <https://doi.org/10.1111/j.1365-2133.2012.11177.x>
71. Abramovits W, Oquendo M. Hydrocortisone butyrate 0.1% lipocream in pediatric patients with atopic dermatitis. *Skinmed*. 2010;8(2):72-79.
72. Hanifin J, Gupta AK, Rajagopalan R. Intermittent dosing of fluticasone propionate cream for reducing the risk of relapse in atopic dermatitis patients. *Br J Dermatol*. 2002;147(3):528-537. <https://doi.org/10.1046/j.1365-2133.2002.05006.x>
73. Matheson R, Kempers S, Breneman D, et al. Hydrocortisone butyrate 0.1% lotion in the treatment of atopic dermatitis in pediatric subjects. *J Drugs Dermatol*. 2008;7(3):266-271.
74. Abbasi S, Kamalinejad M, Babaie D, et al. A new topical treatment of atopic dermatitis in pediatric patients based on Ficus carica L. (Fig): a randomized, placebo-controlled clinical trial. *Complement Ther Med*. 2017;35:85-91. <https://doi.org/10.1016/j.ctim.2017.10.003>
75. Canpolat F, Erkoçoğlu M, Tezer H, Kocabaş CN, Kandi B. Hydrocortisone acetate alone or combined with mupirocin for atopic dermatitis in infants under two years of age - a randomized double blind pilot trial. *Eur Rev Med Pharmacol Sci*. 2012;16(14):1989-1993.
76. Hebert AA, Cook-Bolden FE, Basu S, Calvarese B, Trancik RJ. Safety and efficacy of desonide hydrogel 0.05% in pediatric subjects with atopic dermatitis. *J Drugs Dermatol*. 2007;6(2):175-181.
77. Paller AS, Nimmagadda S, Schachner L, et al. Fluocinolone acetonide 0.01% in peanut oil: therapy for childhood atopic dermatitis, even in patients who are peanut sensitive. *J Am Acad Dermatol*. 2003;48(4):569-577. <https://doi.org/10.1067/mjd.2003.174>
78. Glazenburg EJ, Wolkerstorfer A, Gerretsen AL, Mulder PG, Oranje AP. Efficacy and safety of fluticasone propionate 0.005% ointment in the long-term maintenance treatment of children with atopic dermatitis: differences between boys and girls? *Pediatr Allergy Immunol*. 2009;20(1):59-66. <https://doi.org/10.1111/j.1399-3038.2008.00735.x>
79. Rubio-Gomis E, Martinez-Mir I, Morales-Olivas FJ, et al. Fluticasone in mild to moderate atopic dermatitis relapse: a randomized controlled trial. *Allergol Immunopathol (Madr)*. 2018;46(4):378-384. <https://doi.org/10.1016/j.aller.2017.12.001>
80. Eichenfield LF, Gower RG, Xu J, et al. Once-daily crisaborole ointment, 2%, as a long-term maintenance treatment in patients aged ≥ 3 months with mild-to-moderate atopic dermatitis: a 52-week clinical study. *Am J Clin Dermatol*. 2023;24(4):623-635. <https://doi.org/10.1007/s40257-023-00780-w>

81. Eichenfield LF, Yosipovitch G, Stein Gold LF, et al. Improvement in disease severity and pruritus outcomes with crisaborole ointment, 2%, by baseline atopic dermatitis severity in children and adolescents with mild-to-moderate atopic dermatitis. *Pediatr Dermatol*. 2020;37(6):1030-1037. <https://doi.org/10.1111/pde.14328>
82. Fujita K, Yagi M, Moriawaki S, Yoshida M, Graham D. A phase 2b, randomized, double-blind, multicenter, vehicle-controlled study to assess the efficacy and safety of two crisaborole regimens in Japanese patients aged 2 years and older with mild-to-moderate atopic dermatitis. *J Dermatol*. 2021;48(11):1640-1651. <https://doi.org/10.1111/1346-8138.16120>
83. Luger TA, Hebert AA, Zaenglein AL, et al. Subgroup analysis of crisaborole for mild-to-moderate atopic dermatitis in children aged 2 to < 18 years. *Paediatr Drugs*. 2022;24(2): 175-183. <https://doi.org/10.1007/s40272-021-00490-y>
84. Ma L, Zhang L, Kobayashi M, et al. Efficacy and safety of crisaborole ointment in Chinese and Japanese patients aged ≥ 2 years with mild-to-moderate atopic dermatitis. *J Dermatol*. 2023;50(7):847-855. <https://doi.org/10.1111/1346-8138.16792>
85. NCT04360187. Crisaborole for Chinese and Japanese Subjects (≥ 2 Years of Age) With Mild to Moderate Atopic Dermatitis. 2022.. Accessed January 6, 2026. <https://clinicaltrials.gov/study/NCT04360187>
86. Paller AS, Tom WL, Lebwohl MG, et al. Efficacy and safety of crisaborole ointment, a novel, nonsteroidal phosphodiesterase 4 (PDE4) inhibitor for the topical treatment of atopic dermatitis (AD) in children and adults. *J Am Acad Dermatol*. 2016;75(3): 494-503.e6. <https://doi.org/10.1016/j.jaad.2016.05.046>
87. Simpson EL, Paller AS, Boguniewicz M, et al. Crisaborole ointment improves quality of life of patients with mild to moderate atopic dermatitis and their families. *Dermatol Ther (Heidelb)*. 2018;8(4):605-619. <https://doi.org/10.1007/s13555-018-0263-0>
88. Eichenfield L, Boguniewicz M, Simpson E, et al. Once-daily roflumilast cream 0.15% for atopic dermatitis: pooled results: from integument-1/2 phase 3 trials. *Ann Allergy Asthma Immunol*. 2023;131(5):S91. <https://doi.org/10.1016/j.ana.2023.08.273>
89. Gooderham M, Kircik L, Zirwas M, et al. The safety and efficacy of roflumilast cream 0.15% and 0.05% in patients with atopic dermatitis: randomized, double-blind, phase 2 proof of concept study. *J Drugs Dermatol*. 2023;22(2):139-147. <https://doi.org/10.36849/jdd.7295>
90. Eichenfield LF, Serrao R, Prajapati VH, et al. Efficacy and safety of once-daily roflumilast cream 0.05% in pediatric patients aged 2-5 years with mild-to-moderate atopic dermatitis (INTEGUMENT-PED): a phase 3 randomized controlled trial. *Pediatr Dermatol*. 2025;42(2):296-304. <https://doi.org/10.1111/pde.15840>
91. Papp K, Szepletowski JC, Kircik L, et al. Efficacy and safety of ruxolitinib cream for the treatment of atopic dermatitis: results from 2 phase 3, randomized, double-blind studies. *J Am Acad Dermatol*. 2021;85(4):863-872. <https://doi.org/10.1016/j.jaad.2021.04.085>
92. Eichenfield LF, Stein Gold LF, Simpson EL, et al. Efficacy and safety of ruxolitinib cream in children aged 2 to 11 years with atopic dermatitis: results from TRuE-AD3, a phase 3, randomized double-blind study. *J Am Acad Dermatol*. 2025;93(3): 689-698. <https://doi.org/10.1016/j.jaad.2025.05.1385>
93. Paller AS, Stein Gold L, Soung J, Tallman AM, Rubenstein DS, Gooderham M. Efficacy and patient-reported outcomes from a phase 2b, randomized clinical trial of tapinarof cream for the treatment of adolescents and adults with atopic dermatitis. *J Am Acad Dermatol*. 2021;84(3):632-638. <https://doi.org/10.1016/j.jaad.2020.05.135>
94. Peppers J, Paller AS, Maeda-Chubachi T, et al. A phase 2, randomized dose-finding study of tapinarof (GSK2894512 cream) for the treatment of atopic dermatitis. *J Am Acad Dermatol*. 2019;80(1):89-98.e3. <https://doi.org/10.1016/j.jaad.2018.06.047>
95. Silverberg JL, Eichenfield LF, Hebert AA, et al. Tapinarof cream 1% once daily: significant efficacy in the treatment of moderate to severe atopic dermatitis in adults and children down to 2 years of age in the pivotal phase 3 ADORING trials. *J Am Acad Dermatol*. 2024;91:457-465. <https://doi.org/10.1016/j.jaad.2024.05.023>
96. Tzung TY, Lin CB, Chen YH, Yang CY. Pimecrolimus and narrowband UVB as monotherapy or combination therapy in children and adolescents with atopic dermatitis. *Acta Derm Venereol*. 2006;86(1):34-38. <https://doi.org/10.1080/00015550510044163>
97. Musters AH, Mashayekhi S, Harvey J, et al. Phototherapy for atopic eczema. *Cochrane Database Syst Rev*. 2021;10(10): CD013870. <https://doi.org/10.1002/14651858.CD013870.pub2>
98. Blauvelt A, Guttman-Yassky E, Paller AS, et al. Long-term efficacy and safety of dupilumab in adolescents with moderate-to-severe atopic dermatitis: results through week 52 from a phase III open-label extension trial (LIBERTY AD PED-OLE). *Am J Clin Dermatol*. 2022;23(3):365-383. <https://doi.org/10.1007/s40257-022-00683-2>
99. Paller AS, Siegfried EC, Thaçi D, et al. Efficacy and safety of dupilumab with concomitant topical corticosteroids in children 6 to 11 years old with severe atopic dermatitis: a randomized, double-blinded, placebo-controlled phase 3 trial. *J Am Acad Dermatol*. 2020;83(5):1282-1293. <https://doi.org/10.1016/j.jaad.2020.06.054>
100. Paller AS, Simpson EL, Siegfried EC, et al. Dupilumab in children aged 6 months to younger than 6 years with uncontrolled atopic dermatitis: a randomised, double-blind, placebo-controlled, phase 3 trial. *Lancet*. 2022;400(10356): 908-919. [https://doi.org/10.1016/s0140-6736\(22\)01539-2](https://doi.org/10.1016/s0140-6736(22)01539-2)
101. Simpson EL, Paller AS, Siegfried EC, et al. Efficacy and safety of dupilumab in adolescents with uncontrolled moderate to severe atopic dermatitis: a phase 3 randomized clinical trial. *JAMA Dermatol*. 2020;156(1):44-56. <https://doi.org/10.1001/jamadermatol.2019.3336>
102. Paller AS, Flohr C, Cork M, et al. Efficacy and safety of tralokinumab in adolescents with moderate to severe atopic dermatitis: the phase 3 ECZTRA 6 randomized clinical trial. *JAMA Dermatol*. 2023;159(6):596-605. <https://doi.org/10.1001/jamadermatol.2023.0627>
103. Hebert AA, Flohr C, Hong HC, et al. Efficacy of lebrikizumab in adolescent patients with moderate-to-severe atopic dermatitis: 16-week results from three randomized phase 3 clinical trials. *J Dermatolog Treat*. 2024;35(1):2324833. <https://doi.org/10.1080/09546634.2024.2324833>
104. Paller AS, Flohr C, Eichenfield LF, et al. Safety and efficacy of Lebrikizumab in adolescent patients with moderate-to-severe atopic dermatitis: a 52-Week, open-label, phase 3 study. *Dermatol Ther (Heidelb)*. 2023;13(7):1517-1534. <https://doi.org/10.1007/s13555-023-00942-y>
105. Simpson EL, Gooderham M, Wollenberg A, et al. Efficacy and safety of lebrikizumab in combination with topical corticosteroids in adolescents and adults with moderate-to-severe atopic dermatitis: a randomized clinical trial (ADhere). *JAMA Dermatol*. 2023;159(2):182-191. <https://doi.org/10.1001/jama.2022.5534>

106. Silverberg JI, Wollenberg A, Reich A, et al. Nemolizumab with concomitant topical therapy in adolescents and adults with moderate-to-severe atopic dermatitis (ARCADIA 1 and ARCADIA 2): results from two replicate, double-blind, randomised controlled phase 3 trials. *Lancet*. 2024;404(10451):445-460. [https://doi.org/10.1016/s0140-6736\(24\)01203-0](https://doi.org/10.1016/s0140-6736(24)01203-0)
107. Igarashi A, Katsunuma T, Matsumura T, Komazaki H. Efficacy and safety of nemolizumab in paediatric patients aged 6-12 years with atopic dermatitis with moderate-to-severe pruritus: results from a phase III, randomized, double-blind, placebo-controlled, multicentre study. *Br J Dermatol*. 2023;190(1):20-28. <https://doi.org/10.1093/bjd/ljad268>
108. Guttman-Yassky E, Teixeira HD, Simpson EL, et al. Once-daily upadacitinib versus placebo in adolescents and adults with moderate-to-severe atopic dermatitis (measure up 1 and measure up 2): results from two replicate double-blind, randomised controlled phase 3 trials. *Lancet*. 2021;397(10290):2151-2168. [https://doi.org/10.1016/s0140-6736\(21\)00588-2](https://doi.org/10.1016/s0140-6736(21)00588-2)
109. Paller AS, Ladizinski B, Mendes-Bastos P, et al. Efficacy and safety of upadacitinib treatment in adolescents with moderate-to-severe atopic dermatitis: analysis of the measure up 1, measure up 2, and AD up randomized clinical trials. *JAMA Dermatol*. 2023;159(5):526-535. <https://doi.org/10.1001/jamadermatol.2023.0391>
110. Katoh N, Ohya Y, Murota H, et al. A phase 3 randomized, multicenter, double-blind study to evaluate the safety of upadacitinib in combination with topical corticosteroids in adolescent and adult patients with moderate-to-severe atopic dermatitis in Japan (rising up): an interim 24-week analysis. *JAAD Int*. 2022;6:27-36. <https://doi.org/10.1016/j.jdin.2021.11.001>
111. Katoh N, Ohya Y, Murota H, et al. Safety and efficacy of upadacitinib for atopic dermatitis in Japan: 2-year interim results from the phase 3 rising up study. *Dermatol Ther (Heidelb)*. 2023;13(1):221-234. <https://doi.org/10.1007/s13555-022-00842-7>
112. Reich K, Teixeira HD, de Bruin-Weller M, et al. Safety and efficacy of upadacitinib in combination with topical corticosteroids in adolescents and adults with moderate-to-severe atopic dermatitis (AD up): results from a randomised, double-blind, placebo-controlled, phase 3 trial. *Lancet*. 2021;397(10290):2169-2181. [https://doi.org/10.1016/s0140-6736\(21\)00589-4](https://doi.org/10.1016/s0140-6736(21)00589-4)
113. Cork MJ, McMichael A, Teng J, et al. Impact of oral abrocitinib on signs, symptoms and quality of life among adolescents with moderate-to-severe atopic dermatitis: an analysis of patient-reported outcomes. *J Eur Acad Dermatol Venereol*. 2022;36(3):422-433. <https://doi.org/10.1111/jdv.17792>
114. Silverberg JI, Simpson EL, Thyssen JP, et al. Efficacy and safety of abrocitinib in patients with moderate-to-severe atopic dermatitis: a randomized clinical trial. *JAMA Dermatol*. 2020;156(8):863-873. <https://doi.org/10.1001/jamadermatol.2020.1406>
115. Simpson EL, Silverberg JI, Nosbaum A, et al. Integrated safety analysis of abrocitinib for the treatment of moderate-to-severe atopic dermatitis from the phase II and phase III clinical trial program. *Am J Clin Dermatol*. 2021;22(5):693-707. <https://doi.org/10.1007/s40257-021-00618-3>
116. Simpson EL, Sinclair R, Forman S, et al. Efficacy and safety of abrocitinib in adults and adolescents with moderate-to-severe atopic dermatitis (JADE MONO-1): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial. *Lancet*. 2020;396(10246):255-266. [https://doi.org/10.1016/s0140-6736\(20\)30732-7](https://doi.org/10.1016/s0140-6736(20)30732-7)
117. Eichenfield LF, Flohr C, Sidbury R, et al. Efficacy and safety of abrocitinib in combination with topical therapy in adolescents with moderate-to-severe atopic dermatitis: the JADE TEEN randomized clinical trial. *JAMA Dermatol*. 2021;157(10):1165-1173. <https://doi.org/10.1001/jamadermatol.2021.2830>
118. Torrelo A, Rewerska B, Galimberti M, et al. Efficacy and safety of baricitinib in combination with topical corticosteroids in paediatric patients with moderate-to-severe atopic dermatitis with an inadequate response to topical corticosteroids: results from a phase III, randomized, double-blind, placebo-controlled study (BREEZE-AD PEDS). *Br J Dermatol*. 2023;189(1):23-32. <https://doi.org/10.1093/bjd/ljad096>
119. Flohr C, Rosala-Hallas A, Jones AP, et al. Efficacy and safety of ciclosporin versus methotrexate in the treatment of severe atopic dermatitis in children and young people (TREAT): a multicentre, parallel group, assessor-blinded clinical trial. *Br J Dermatol*. 2023;189:674-684. <https://doi.org/10.1093/bjd/ljad281>
120. Francis NA, Ridd MJ, Thomas-Jones E, et al. Oral and topical antibiotics for clinically infected eczema in children: a pragmatic randomized controlled trial in ambulatory care. *Ann Fam Med*. 2017;15(2):124-130. <https://doi.org/10.1370/afm.2038>
121. Haeck IM, Knol MJ, Ten Berge O, van Velsen SG, de Bruin-Weller MS, Bruijnzeel-Koomen CA. Enteric-coated mycophenolate sodium versus cyclosporin A as long-term treatment in adult patients with severe atopic dermatitis: a randomized controlled trial. *J Am Acad Dermatol*. 2011;64(6):1074-1084. <https://doi.org/10.1016/j.jaad.2010.04.027>
122. Phan K, Smith SD. Mycophenolate mofetil and atopic dermatitis: systematic review and meta-analysis. *J Dermatolog Treat*. 2020;31(8):810-814. <https://doi.org/10.1080/09546634.2019.1642996>
123. Berth-Jones J, Takwale A, Tan E, et al. Azathioprine in severe adult atopic dermatitis: a double-blind, placebo-controlled, crossover trial. *Br J Dermatol*. 2002;147(2):324-330. <https://doi.org/10.1046/j.1365-2133.2002.04989.x>
124. Meggitt SJ, Gray JC, Reynolds NJ. Azathioprine dosed by thiopurine methyltransferase activity for moderate-to-severe atopic eczema: a double-blind, randomised controlled trial. *Lancet*. 2006;367(9513):839-846. [https://doi.org/10.1016/s0140-6736\(06\)68340-2](https://doi.org/10.1016/s0140-6736(06)68340-2)
125. Goujon C, Viguier M, Staumont-Salle D, et al. Methotrexate versus cyclosporine in adults with moderate-to-severe atopic dermatitis: a phase III randomized noninferiority trial. *J Allergy Clin Immunol Pract*. 2018;6(2):562-569.e3. <https://doi.org/10.1016/j.jaip.2017.07.007>
126. Granlund H, Erkkö P, Remitz A, et al. Comparison of cyclosporin and UVAB phototherapy for intermittent one-year treatment of atopic dermatitis. *Acta Derm Venereol*. 2001;81(1):22-27. <https://doi.org/10.1080/00015550120235>
127. Koppelman U, Poulsen J, Grunnet N, Deleuran MS, Obitz E. Cyclosporine and extracorporeal photopheresis are equipotent in treating severe atopic dermatitis: a randomized cross-over study comparing two efficient treatment modalities. *Front Med (Lausanne)*. 2014;1:33. <https://doi.org/10.3389/fmed.2014.00033>
128. Pacor ML, Di Lorenzo G, Martinelli N, Mansueto P, Rini GB, Corrocher R. Comparing tacrolimus ointment and oral cyclosporine in adult patients affected by atopic dermatitis: a randomized study. *Clin Exp Allergy*. 2004;34(4):639-645. <https://doi.org/10.1111/j.1365-2222.2004.1907.x>

129. Schmitt J, Schäkel K, Fölster-Holst R, et al. Prednisolone vs. ciclosporin for severe adult eczema. An investigator-initiated double-blind placebo-controlled multicentre trial. *Br J Dermatol*. 2010;162(3):661-668. <https://doi.org/10.1111/j.1365-2133.2009.09561.x>
130. Hanifin JM, Paller AS, Eichenfield L, et al. Efficacy and safety of tacrolimus ointment treatment for up to 4 years in patients with atopic dermatitis. *J Am Acad Dermatol*. 2005;53(2 Suppl 2):S186-S194. <https://doi.org/10.1016/j.jaad.2005.04.062>
131. Kang S, Lucky AW, Pariser D, Lawrence I, Hanifin JM. Long-term safety and efficacy of tacrolimus ointment for the treatment of atopic dermatitis in children. *J Am Acad Dermatol*. 2001;44(1 Suppl):S58-S64. <https://doi.org/10.1067/mjd.2001.109812>
132. Patel RR, Vander Straten MR, Korman NJ. The safety and efficacy of tacrolimus therapy in patients younger than 2 years with atopic dermatitis. *Arch Dermatol*. 2003;139(9):1184-1186. <https://doi.org/10.1001/archderm.139.9.1184>
133. Perälä M, Ahola M, Mikkola T, Pelkonen AS, Remitz A, Mäkelä MJ. Young children with moderate-to-severe atopic dermatitis can be treated safely and effectively with either topical tacrolimus or mild corticosteroids. *Acta Paediatr*. 2020;109(3):550-556. <https://doi.org/10.1111/apa.15001>
134. Reitamo S, Rustin M, Harper J, et al. A 4-year follow-up study of atopic dermatitis therapy with 0.1% tacrolimus ointment in children and adult patients. *Br J Dermatol*. 2008;159(4):942-951. <https://doi.org/10.1111/j.1365-2133.2008.08747.x>
135. Remitz A, Harper J, Rustin M, et al. Long-term safety and efficacy of tacrolimus ointment for the treatment of atopic dermatitis in children. *Acta Derm Venereol*. 2007;87(1):54-61. <https://doi.org/10.2340/00015555-0167>
136. Salava A, Perälä M, Pelkonen A, Mäkelä M, Remitz A. Safety of tacrolimus 0.03% and 0.1% ointments in young children with atopic dermatitis: a 36-month follow-up study. *Clin Exp Dermatol*. 2022;47(5):889-902. <https://doi.org/10.1111/ced.15024>
137. Tan J, Langley R. Safety and efficacy of tacrolimus ointment 0.1% (Protopic) in atopic dermatitis: a Canadian open-label multicenter study. *J Cutan Med Surg*. 2004;8(4):213-219. <https://doi.org/10.1007/s10227-003-0115-z>
138. Caron AGM, Bloem M, El Khattabi H, et al. The wide variety of methotrexate dosing regimens for the treatment of atopic dermatitis: a systematic review. *J Dermatol Treat*. 2024;35(1):2292962. <https://doi.org/10.1080/09546634.2023.2292962>
139. Johnson H, Aquino MR, Snyder A, et al. Prevalence of allergic contact dermatitis in children with and without atopic dermatitis: a multicenter retrospective case-control study. *J Am Acad Dermatol*. 2023;89(5):1007-1014. <https://doi.org/10.1016/j.jaad.2023.06.048>
140. Chopra R, Vakharia PP, Sacotte R, Silverberg JI. Efficacy of bleach baths in reducing severity of atopic dermatitis: a systematic review and meta-analysis. *Ann Allergy Asthma Immunol*. 2017;119(5):435-440. <https://doi.org/10.1016/j.anai.2017.08.289>
141. Huang JT, Abrams M, Tlougan B, Rademaker A, Paller AS. Treatment of *Staphylococcus aureus* colonization in atopic dermatitis decreases disease severity. *Pediatrics*. 2009;123(5):e808-e814. <https://doi.org/10.1542/peds.2008-2217>
142. Huang JT, Rademaker A, Paller AS. Dilute bleach baths for *Staphylococcus aureus* colonization in atopic dermatitis to decrease disease severity. *Arch Dermatol*. 2011;147(2):246-247. <https://doi.org/10.1001/archdermatol.2010.434>
143. Arellano FM, Wentworth CE, Arana A, Fernández C, Paul CF. Risk of lymphoma following exposure to calcineurin inhibitors and topical steroids in patients with atopic dermatitis. *J Invest Dermatol*. 2007;127(4):808-816. <https://doi.org/10.1038/sj.jid.5700622>
144. Schneeweiss S, Doherty M, Zhu S, et al. Topical treatments with pimecrolimus, tacrolimus and medium- to high-potency corticosteroids, and risk of lymphoma. *Dermatology*. 2009;219(1):7-21. <https://doi.org/10.1159/000209289>
145. Hui RL, Lide W, Chan J, Schottinger J, Yoshinaga M, Millares M. Association between exposure to topical tacrolimus or pimecrolimus and cancers. *Ann Pharmacother*. 2009;43(12):1956-1963. <https://doi.org/10.1345/aph.1M278>
146. Paller AS, Fölster-Holst R, Chen SC, et al. No evidence of increased cancer incidence in children using topical tacrolimus for atopic dermatitis. *J Am Acad Dermatol*. 2020;83(2):375-381. <https://doi.org/10.1016/j.jaad.2020.03.075>
147. Castellsague J, Kuiper JG, Pottegård A, et al. A cohort study on the risk of lymphoma and skin cancer in users of topical tacrolimus, pimecrolimus, and corticosteroids (Joint European Longitudinal Lymphoma and Skin Cancer Evaluation - JOELLE study). *Clin Epidemiol*. 2018;10:299-310. <https://doi.org/10.2147/clep.S146442>
148. Paller AS. Chapter 3: eczematous eruptions in childhood. In: Paller AS, Mancini AJ, eds. *Hurwitz clinical pediatric dermatology*. Elsevier, Inc.; 2011:49.
149. Maleki-Yazdi KA, Heen AF, Zhao IX, et al. Values and preferences of patients and caregivers regarding treatment of atopic dermatitis (eczema): a systematic review. *JAMA Dermatol*. 2023;159(3):320-330. <https://doi.org/10.1001/jamadermatol.2022.6045>
150. Ratley G, Sun AA, Capozza K, Barta K, Myles IA. Survey of topical exposure concerns for patients and caregivers dealing with atopic dermatitis. *Front Allergy*. 2023;4:1210973. <https://doi.org/10.3389/falgy.2023.1210973>
151. Zebda R, Paller AS. Phosphodiesterase 4 inhibitors. *J Am Acad Dermatol*. 2018;78(3 Suppl 1):S43-S52. <https://doi.org/10.1016/j.jaad.2017.11.056>
152. Draelos ZD, Feldman SR, Berman B, et al. Tolerability of topical treatments for atopic dermatitis. *Dermatol Ther (Heidelb)*. 2019;9(1):71-102. <https://doi.org/10.1007/s13555-019-0280-7>
153. Simpson EL, Eichenfield LF, Papp KA, et al. Long-term safety and efficacy with roflumilast cream 0.15% in patients aged ≥6 years with atopic dermatitis: a phase 3 open-label extension trial. *Dermatitis*. 2026;37:75-83. <https://doi.org/10.1089/derm.2024.0418>
154. Lax SJ, Van Vogt E, Candy B, et al. Topical anti-inflammatory treatments for eczema: network meta-analysis. *Cochrane Database Syst Rev*. 2024;8(8):CD015064. <https://doi.org/10.1002/14651858.CD015064.pub2>
155. Papp K, Szepletowski JC, Kircik L, et al. Long-term safety and disease control with ruxolitinib cream in atopic dermatitis: results from two phase 3 studies. *J Am Acad Dermatol*. 2023;88(5):1008-1016. <https://doi.org/10.1016/j.jaad.2022.09.060>
156. Chan S, Cornelius V, Cro S, Harper JI, Lack G. Treatment effect of omalizumab on severe pediatric atopic dermatitis: the ADAPT randomized clinical trial. *JAMA Pediatr*. 2020;174(1):29-37. <https://doi.org/10.1001/jamapediatrics.2019.4476>
157. Wang H-H, Li Y-C, Huang Y-C. Efficacy of omalizumab in patients with atopic dermatitis: a systematic review and meta-analysis. *J Allergy Clin Immunol*. 2016;138(6):1719-1722.e1. <https://doi.org/10.1016/j.jaci.2016.05.038>
158. Holm J, Agner T, Sand C, Thomsen S. Omalizumab for atopic dermatitis: case series and a systematic review of the literature. *Int J Dermatol*. 2017;56:18-26. <https://doi.org/10.1111/ijd.13353>

159. El-Khalawany MA, Hassan H, Shaaban D, Ghonaim N, Eassa B. Methotrexate versus cyclosporine in the treatment of severe atopic dermatitis in children: a multicenter experience from Egypt. *Eur J Pediatr*. 2013;172(3):351-356. <https://doi.org/10.1007/s00431-012-1893-3>
160. Siegels D, Heratizadeh A, Abraham S, et al. Systemic treatments in the management of atopic dermatitis: a systematic review and meta-analysis. *Allergy*. 2021;76(4):1053-1076. <https://doi.org/10.1111/all.14631>
161. Ridd MJ, Santer M, MacNeill SJ, et al. Effectiveness and safety of lotion, cream, gel, and ointment emollients for childhood eczema: a pragmatic, randomised, phase 4, superiority trial. *Lancet Child Adolesc Health*. 2022;6(8):522-532. [https://doi.org/10.1016/S2352-4642\(22\)00146-8](https://doi.org/10.1016/S2352-4642(22)00146-8)